1
|
Battesti G, Jachiet M, Lepelletier C, Petit A, Vignon-Pennamen MD, Cassius C, de Masson A, Battistella M, Bagot M, Bouaziz JD, Mahévas T. Two cases of dupilumab-responsive Kimura disease. Clin Exp Dermatol 2024; 49:502-506. [PMID: 38149974 DOI: 10.1093/ced/llad455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 11/07/2023] [Accepted: 12/04/2023] [Indexed: 12/28/2023]
Abstract
Kimura disease (KD) is a rare, chronic angiolymphoproliferative inflammatory disease appearing to be mostly restricted to the skin and soft tissue. Cutaneous involvement of KD includes head and/or neck nodules showing suggestive histological features, frequently associated with an atopic dermatitis-like or prurigo-like presentation. KD is challenging to treat, with high rate of recurrence using current therapeutic strategies. Evidence for involvement of a T-helper type 2 (Th2) immune response in KD pathogenesis has been found in previous studies. Consequently, this study aimed to determine the efficacy and safety of dupilumab, a human monoclonal antibody that inhibits signalling of key Th2 cytokines, interleukin (IL)-4 and IL-13, within a single-centre cohort of patients with cutaneous KD. Two adults with a diagnosis of refractory (failure of at least one treatment line) cutaneous-restricted KD based on clinical, biological, histological, molecular and imaging findings received dupilumab for KD, and showed dramatic response with a good safety profile.
Collapse
Affiliation(s)
- Gilles Battesti
- Departments of Dermatology
- Université Paris Cité, Paris, France
| | | | | | | | | | - Charles Cassius
- Departments of Dermatology
- Université Paris Cité, Paris, France
| | - Adèle de Masson
- Departments of Dermatology
- Université Paris Cité, Paris, France
| | - Maxime Battistella
- Université Paris Cité, Paris, France
- Pathology, Saint-Louis Hospital, Paris, France
| | - Martine Bagot
- Departments of Dermatology
- Université Paris Cité, Paris, France
| | | | | |
Collapse
|
2
|
Mahévas T, Osio A, Larcher L, Clappier E, Kempf W, Adès L, Fenaux P, Sébert M, Delaleu J, Jachiet M, Cordoliani F, Charvet E, Carpentier O, Itzykson RA, Weinborn M, Mardare N, Marco-Bonnet J, de Masson A, Duployez N, Huynh T, Bouaziz JD, Vignon-Pennamen MD, Battistella M. Cutaneous clonal mature plasmacytoid dendritic cell dermatosis in patients with myeloid neoplasms. Blood Adv 2024:bloodadvances.2023012489. [PMID: 38621250 DOI: 10.1182/bloodadvances.2023012489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/27/2024] [Accepted: 03/04/2024] [Indexed: 04/17/2024] Open
Affiliation(s)
- Thibault Mahévas
- Service de Dermatologie, Hôpital Saint-Louis, Paris, Paris, France
| | | | - Lise Larcher
- Service d'hématologie biologique, Hôpital Saint-Louis AP-HP, Paris ; France 4 Université Paris Cité, Génomes, biologie cellulaire et thérapeutique U944, INSERM, CNRS, F-75010 Paris, France, France
| | - Emmanuelle Clappier
- Service d'hématologie biologique, Hôpital Saint-Louis AP-HP, Paris ; France 4 Université Paris Cité, Génomes, biologie cellulaire et thérapeutique U944, INSERM, CNRS, F-75010 Paris, France, France
| | - Werner Kempf
- Kempf und Pfaltz Histologische Diagnostik, Zurich, Switzerland
| | | | | | | | | | | | | | - Estelle Charvet
- Service de Dermatologie, APHP, Hôpital Saint-Louis, Paris, Paris, France
| | | | | | - Marie Weinborn
- Laboratoire d'anatomie et cytologie pathologique, C .H. de Valenciennes, Valenciennes, France, Valenciennes, France
| | | | | | | | | | - Tony Huynh
- Hopital Saint-Louis, Universite de Paris-Cite, Paris, France
| | | | | | | |
Collapse
|
3
|
Kempf W, Mitteldorf C, Cerroni L, Willemze R, Berti E, Guenova E, Scarisbrick JJ, Battistella M. Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group. J Eur Acad Dermatol Venereol 2024. [PMID: 38581201 DOI: 10.1111/jdv.19987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Accepted: 02/28/2024] [Indexed: 04/08/2024]
Abstract
The classification of primary cutaneous lymphomas and lymphoproliferative disorders (LPD) is continuously evolving by integrating novel clinical, pathological and molecular data. Recently two new classifications for haematological malignancies including entities of cutaneous lymphomas were proposed: the 5th edition of the WHO classification of haematolymphoid tumours and the International Consensus Classification (ICC) of mature lymphoid neoplasms. This article provides an overview of the changes introduced in these two classifications compared to the previous WHO classification. The main changes shared by both classifications include the downgrading of CD8+ acral T-cell lymphoma to CD8+ acral T-cell LPD, and the recognition of entities that were previously categorized as provisional and have now been designated as definite types including primary cutaneous small or medium CD4+ T-cell LPD, primary cutaneous gamma/delta T-cell lymphoma, primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, Epstein-Barr virus-positive mucocutaneous ulcer. Both classifications consider primary cutaneous marginal zone B-cell clonal neoplasm as an indolent disease but use a different terminology: primary cutaneous marginal zone lymphoma (WHO) and primary cutaneous marginal zone LPD (ICC). The 5th WHO classification further introduces and provides essential and desirable diagnostic criteria for each disease type and includes chapters on reactive B- or T-cell rich lymphoid proliferations formerly referred as cutaneous pseudolymphomas, as well as histiocyte and CD8 T-cell rich LPD in patients with inborn error of immunity. As already emphasized in previous lymphoma classifications, the importance of integrating clinical, histological, phenotypic and molecular features remains the crucial conceptual base for defining cutaneous (and extracutaneous) lymphomas.
Collapse
Affiliation(s)
- W Kempf
- Kempf und Pfaltz Histologische Diagnostik, Zurich, Switzerland
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
| | - C Mitteldorf
- Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany
| | - L Cerroni
- Research Unit of Dermatopathology, Department of Dermatology, Medical University of Graz, Graz, Austria
| | - R Willemze
- Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands
| | - E Berti
- Department of Dermatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - E Guenova
- Department of Dermatology, Lausanne University Hospital, Lausanne, Switzerland
- Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - J J Scarisbrick
- Centre for Rare Diseases, University Hospital of Birmingham, Birmingham, UK
| | - M Battistella
- Service de Pathologie, Hôpital Saint-Louis, AP-HP, Paris, France
- Inserm U976 "Human Immunology, Pathophysiology and Immunotherapy", Université Paris Cité, Paris, France
| |
Collapse
|
4
|
Reger De Moura C, Louveau B, Jouenne F, Vilquin P, Battistella M, Bellahsen-Harrar Y, Sadoux A, Menashi S, Dumaz N, Lebbé C, Mourah S. Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1. Oncogene 2024:10.1038/s41388-024-03014-3. [PMID: 38570692 DOI: 10.1038/s41388-024-03014-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 03/15/2024] [Accepted: 03/21/2024] [Indexed: 04/05/2024]
Abstract
The role of the focal adhesion protein kindlin-3 as a tumor suppressor and its interaction mechanisms with extracellular matrix constitute a major field of investigation to better decipher tumor progression. Besides the well-described role of kindlin-3 in integrin activation, evidence regarding modulatory functions between melanoma cells and tumor microenvironment are lacking and data are needed to understand mechanisms driven by kindlin-3 inactivation. Here, we show that kindlin-3 inactivation through knockdown or somatic mutations increases BRAFV600mut melanoma cells oncogenic properties via collagen-related signaling by decreasing cell adhesion and enhancing proliferation and migration in vitro, and by promoting tumor growth in mice. Mechanistic analysis reveals that kindlin-3 interacts with the collagen-activated tyrosine kinase receptor DDR1 (Discoidin domain receptor 1) modulating its expression and its interaction with β1-integrin. Kindlin-3 knockdown or mutational inactivation disrupt DDR1/β1-integrin complex in vitro and in vivo and its loss improves the anti-proliferative effect of DDR1 inhibition. In agreement, kindlin-3 downregulation is associated with DDR1 over-expression in situ and linked to worse melanoma prognosis. Our study reveals a unique mechanism of action of kindlin-3 in the regulation of tumorigenesis mediated by the collagen-activated tyrosine kinase receptor DDR1 thus paving the way for innovative therapeutic targeting approaches in melanoma.
Collapse
Affiliation(s)
- Coralie Reger De Moura
- Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France
- Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France
| | - Baptiste Louveau
- Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France
- Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France
| | - Fanélie Jouenne
- Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France
- Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France
| | - Paul Vilquin
- Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France
| | - Maxime Battistella
- Department of Pathology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France
| | - Yaelle Bellahsen-Harrar
- Department of Pathology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France
| | - Aurélie Sadoux
- Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France
| | - Suzanne Menashi
- Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France
- Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France
| | - Nicolas Dumaz
- Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France
| | - Céleste Lebbé
- Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France
- Department of Dermatology and CIC, Hôpital Saint Louis, Cancer Institute, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France
| | - Samia Mourah
- Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France.
- Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France.
| |
Collapse
|
5
|
Soursou C, Battistella M, Begon E, Mauppin C. An Indolent Forearm Plaque: A Quiz. Acta Derm Venereol 2024; 104:adv34883. [PMID: 38567913 PMCID: PMC11005180 DOI: 10.2340/actadv.v104.34883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Accepted: 03/19/2024] [Indexed: 04/05/2024] Open
Abstract
Abstract is missing (Quiz)
Collapse
Affiliation(s)
- Claire Soursou
- Department of Dermatology, René Dubos Hospital, Pontoise, France.
| | | | - Edouard Begon
- Department of Dermatology, René Dubos Hospital, Pontoise, France
| | - Clémence Mauppin
- Department of Dermatology, René Dubos Hospital, Pontoise, France
| |
Collapse
|
6
|
Battesti G, Thonnart N, Bozonnat A, Ram‐Wolff C, de Masson A, Bensussan A, Bagot M, Marie‐Cardine A, Battistella M. CD39 is expressed by a wide range of cutaneous T-cell lymphomas. Skin Health Dis 2024; 4:e334. [PMID: 38577051 PMCID: PMC10988668 DOI: 10.1002/ski2.334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 04/06/2024]
Abstract
CD39, an ectoenzyme in the immunosuppressive CD39/CD73/adenosine pathway, known to promote solid tumour outgrowth and spreading, was investigated in both skin and blood compartments of cutaneous T cell lymphomas. CD39 was overexpressed by peripheral blood T-cells in Sezary syndrome and mycosis fungoides, and in skin-infiltrating lymphocytes of Sezary syndrome, mycosis fungoides, subcutaneous panniculitis-like T-cell lymphoma and primary cutaneous CD30-positive lymphoproliferation. Our study emphasizes the interest in using CD39/CD73/adenosine pathway blocking agents for cutaneous T cell lymphomas treatment.
Collapse
Affiliation(s)
- Gilles Battesti
- Team 1Human Immunology, Pathophysiology, ImmunotherapyINSERM U976ParisFrance
- Université Paris CitéIRSLParisFrance
| | - Nicolas Thonnart
- Team 1Human Immunology, Pathophysiology, ImmunotherapyINSERM U976ParisFrance
- Université Paris CitéIRSLParisFrance
| | - Alizée Bozonnat
- Team 1Human Immunology, Pathophysiology, ImmunotherapyINSERM U976ParisFrance
- Université Paris CitéIRSLParisFrance
| | - Caroline Ram‐Wolff
- Team 1Human Immunology, Pathophysiology, ImmunotherapyINSERM U976ParisFrance
- Université Paris CitéIRSLParisFrance
- Department of DermatologySaint‐Louis HospitalParisFrance
| | - Adèle de Masson
- Team 1Human Immunology, Pathophysiology, ImmunotherapyINSERM U976ParisFrance
- Université Paris CitéIRSLParisFrance
- Department of DermatologySaint‐Louis HospitalParisFrance
| | - Armand Bensussan
- Team 1Human Immunology, Pathophysiology, ImmunotherapyINSERM U976ParisFrance
- Université Paris CitéIRSLParisFrance
| | - Martine Bagot
- Team 1Human Immunology, Pathophysiology, ImmunotherapyINSERM U976ParisFrance
- Université Paris CitéIRSLParisFrance
- Department of DermatologySaint‐Louis HospitalParisFrance
| | - Anne Marie‐Cardine
- Team 1Human Immunology, Pathophysiology, ImmunotherapyINSERM U976ParisFrance
- Université Paris CitéIRSLParisFrance
| | - Maxime Battistella
- Team 1Human Immunology, Pathophysiology, ImmunotherapyINSERM U976ParisFrance
- Université Paris CitéIRSLParisFrance
- Department of PathologySaint‐Louis HospitalParisFrance
| |
Collapse
|
7
|
Vignon-Pennamen MD, Battistella M. From Histiocytoid Sweet Syndrome to Myelodysplasia Cutis: History and Perspectives. Dermatol Clin 2024; 42:209-217. [PMID: 38423682 DOI: 10.1016/j.det.2023.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2024]
Abstract
In 2005, a new histologic variant of Sweet syndrome (SS) has been described and termed histiocytoid SS (HSS). Clinically, patients had a typical SS, but on skin biopsy, the infiltrates were composed of immature nonblast myeloid cells. Nearly 50% of patients with HSS have myelodysplastic syndrome (MDS). HSS may be the first manifestation leading to the diagnosis of MDS. In 2015, a new category of myeloid dermatosis has been proposed, called myelodysplasia cutis, describing the specific skin infiltration by myelodysplastic cells in patients with MDS.
Collapse
Affiliation(s)
| | - Maxime Battistella
- Pathology Department, APHP Nord, Hopital Saint-Louis, Université Paris Cité, Paris, France; INSERM U976 "Human Immunology, Pathophysiology, and Immunotherapy", Paris, France.
| |
Collapse
|
8
|
Giustiniani J, Ta VA, Belkhelouat S, Battistella M, Ouahbi D, Ram-Wolff C, Louveau B, Mourah S, Bagot M, Moins-Teisserenc H, Ortonne N, Bensussan A, De Masson A. Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas. J Invest Dermatol 2024:S0022-202X(24)00259-8. [PMID: 38555062 DOI: 10.1016/j.jid.2024.03.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 02/29/2024] [Accepted: 03/01/2024] [Indexed: 04/02/2024]
Affiliation(s)
- Jérôme Giustiniani
- INSERM U955, Institut Mondor de Recherche Biomédicale, Team Ortonne (Neurofibromatosis and lymphoma oncogenesis - NFL), Créteil, France; Université Paris Est Créteil, Créteil, France
| | - Van Anh Ta
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Sadjia Belkhelouat
- INSERM U955, Institut Mondor de Recherche Biomédicale, Team Ortonne (Neurofibromatosis and lymphoma oncogenesis - NFL), Créteil, France; Université Paris Est Créteil, Créteil, France
| | - Maxime Battistella
- Université Paris Cité, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Pathology Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Dina Ouahbi
- Department of Bioinformatics, Institut de Recherche Saint-Louis, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Baptiste Louveau
- Université Paris Cité, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Department of Solid Tumor Genomics, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Samia Mourah
- Université Paris Cité, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Department of Solid Tumor Genomics, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Martine Bagot
- Université Paris Cité, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Hélène Moins-Teisserenc
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France; Hematology Laboratory, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Nicolas Ortonne
- INSERM U955, Institut Mondor de Recherche Biomédicale, Team Ortonne (Neurofibromatosis and lymphoma oncogenesis - NFL), Créteil, France; Université Paris Est Créteil, Créteil, France; Department of Pathology, Henri Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Creteil, France
| | - Armand Bensussan
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Institut Jean Godinot, Reims, France; Mohammed VI Polytechnic University, Ben Guerir, Morocco
| | - Adèle De Masson
- Université Paris Cité, Paris, France; INSERM U976, Institut de Recherche Saint-Louis, Paris, France; Department of Dermatology, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.
| |
Collapse
|
9
|
Idoudi S, Battistella M, El Zeinaty P, Tavernier C, Lebbe C, Baroudjian B. Line-field confocal optical coherence tomography in vivo description of Sarcoptes scabiei and histological correlation. J Eur Acad Dermatol Venereol 2024. [PMID: 38487987 DOI: 10.1111/jdv.19972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Accepted: 02/28/2024] [Indexed: 05/01/2024]
Affiliation(s)
- Safa Idoudi
- Dermatology Department, Saint Louis Hospital, Paris, France
| | | | | | | | - Celeste Lebbe
- Dermatology Department, Saint Louis Hospital, Paris, France
| | | |
Collapse
|
10
|
Lazaridou I, Alqahtani M, Louveau B, Ram-Wolff C, Alharbi B, Al Hage J, Dumont M, Bouaziz JD, Bagot M, Moins-Teisserenc H, Rivet J, Battistella M, Mourah S, de Masson A. Impact of blood tumour clone frequency on time to next treatment in mycosis fungoides. J Eur Acad Dermatol Venereol 2024. [PMID: 38469982 DOI: 10.1111/jdv.19922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Accepted: 02/13/2024] [Indexed: 03/13/2024]
Affiliation(s)
- Ingrid Lazaridou
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Mohammed Alqahtani
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
| | - Baptiste Louveau
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis University Hospital, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
| | - Bader Alharbi
- King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia
| | - Jana Al Hage
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
| | - Maëlle Dumont
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
| | - Jean-David Bouaziz
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
| | - Martine Bagot
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Hélène Moins-Teisserenc
- Université Paris Cité, Paris, France
- Hematology Laboratory, APHP, Saint-Louis University Hospital, Paris, France
- INSERM U1160, Institute de Recherche Saint-Louis, Paris, France
| | - Jacqueline Rivet
- Department of Pathology, APHP, Saint-Louis University Hospital, Paris, France
| | - Maxime Battistella
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Department of Pathology, APHP, Saint-Louis University Hospital, Paris, France
| | - Samia Mourah
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis University Hospital, Paris, France
| | - Adèle de Masson
- Department of Dermatology, APHP, Saint-Louis University Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
11
|
Macagno N, Kervarrec T, Thanguturi S, Sohier P, Pissaloux D, Mescam L, Jullie ML, Frouin E, Osio A, Faisant M, Le Loarer F, Cribier B, Calonje E, Luna EVE, Massi D, Goto K, Nishida H, Paindavoine S, Houlier A, Tantot J, Benzerdjeb N, Tirode F, De la Fouchardière A, Battistella M. SOX10-Internal Tandem Duplications and PLAG1 or HMGA2 Fusions Segregate Eccrine-Type and Apocrine-Type Cutaneous Mixed Tumors. Mod Pathol 2024; 37:100430. [PMID: 38266920 DOI: 10.1016/j.modpat.2024.100430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 12/26/2023] [Accepted: 01/16/2024] [Indexed: 01/26/2024]
Abstract
Cutaneous mixed tumors exhibit a wide morphologic diversity and are currently classified into apocrine and eccrine types based on their morphologic differentiation. Some cases of apocrine-type cutaneous mixed tumors (ACMT), namely, hyaline cell-rich apocrine cutaneous mixed tumors (HCR-ACMT) show a prominent or exclusive plasmacytoid myoepithelial component. Although recurrent fusions of PLAG1 have been observed in ACMT, the oncogenic driver of eccrine-type cutaneous mixed tumors (ECMT) is still unknown. The aim of the study was to provide a comprehensive morphologic, immunohistochemical, and molecular characterization of these tumors. Forty-one cases were included in this study: 28 cases of ACMT/HCR-ACMT and 13 cases of ECMT. After morphologic and immunohistochemical characterization, all specimens were analyzed by RNA sequencing. By immunohistochemistry, all cases showed expression of SOX10, but only ACMT/HCR-ACMT showed expression of PLAG1 and HMGA2. RNA sequencing confirmed the presence of recurrent fusion of PLAG1 or HMGA2 in all cases of ACMT/HCR-ACMT, with a perfect correlation with PLAG1/HMGA2 immunohistochemical status, and revealed internal tandem duplications of SOX10 (SOX10-ITD) in all cases of ECMT. Although TRPS1::PLAG1 was the most frequent fusion, HMGA2::WIF1 and HMGA2::NFIB were detected in ACMT cases. Clustering analysis based on gene expression profiling of 110 tumors, including numerous histotypes, showed that ECMT formed a distinct group compared with all other tumors. ACMT, HCR-ACMT, and salivary gland pleomorphic adenoma clustered together, whereas myoepithelioma with fusions of EWSR1, FUS, PBX1, PBX3, POU5F1, and KLF17 formed another cluster. Follow-up showed no evidence of disease in 23 cases across all 3 tumor types. In conclusion, our study demonstrated for the first time SOX10-ITD in ECMT and HMGA2 fusions in ACMT and further refined the prevalence of PLAG1 fusions in ACMT. Clustering analyses revealed the transcriptomic distance between these different tumors, especially in the heterogenous group of myoepitheliomas.
Collapse
Affiliation(s)
- Nicolas Macagno
- CARADERM, French Network of Rare Skin Cancers, Lille, France; Department of Pathology, APHM, Timone, Marseille, France; Aix Marseille University, INSERM, MMG, Marseille, France.
| | - Thibault Kervarrec
- CARADERM, French Network of Rare Skin Cancers, Lille, France; Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France; "Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, Tours, France
| | | | - Pierre Sohier
- Department of Pathology, Hôpital Cochin, AP-HP. Centre-Université Paris Cité, Paris, France
| | - Daniel Pissaloux
- Department of Biopathology, Centre Léon Bérard, Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Lenaïg Mescam
- Department of Biopathology, Paoli-Calmettes Institute, Marseille, France
| | - Marie-Laure Jullie
- Department of Pathology, University Hospital of Bordeaux, Bordeaux, France
| | - Eric Frouin
- Department of Pathology, University Hospital of Poitiers, University of Poitiers, LITEC, Poitiers, France
| | - Amelie Osio
- National Center of Dermatopathology, Paris-la Roquette, Ivry, France; Department of Pathology, HCL Lyon-Sud Hospital, Lyon, France
| | | | - François Le Loarer
- Department of Biopathology, Bergonié Institute, Bordeaux, France; Bordeaux Institute of Oncology, BRIC U1312, INSERM, Université de Bordeaux, Institut Bergonié, Bordeaux, France
| | - Bernard Cribier
- Department of Dermatology, University of Strasbourg, Strasbourg, France
| | - Eduardo Calonje
- Department of Dermatopathology, St John's institute of Dermatology, Guy's and St Thomas' NHS trust, London, United Kingdom
| | - Evelyn Vanesa Erazo Luna
- Department of Dermatopathology, St John's institute of Dermatology, Guy's and St Thomas' NHS trust, London, United Kingdom
| | - Daniela Massi
- Section of Pathology, Department of Health Sciences, University of Florence, Florence, Italy
| | - Keisuke Goto
- Department of Diagnostic Pathology, Faculty of Medicine, Oita, Japan
| | - Haruto Nishida
- Department of Diagnostic Pathology, Faculty of Medicine, Oita, Japan
| | | | - Aurelie Houlier
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | - Juliet Tantot
- Department of Pathology, HCL Lyon-Sud Hospital, Lyon, France
| | | | - Franck Tirode
- Department of Biopathology, Centre Léon Bérard, Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Arnaud De la Fouchardière
- Department of Biopathology, Centre Léon Bérard, Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Maxime Battistella
- CARADERM, French Network of Rare Skin Cancers, Lille, France; Department of Pathology, AP-HP Hospital Saint-Louis, INSERM U976, Université Paris Cité, Paris, France
| |
Collapse
|
12
|
Paris J, Wilhelm C, Lebbé C, Elmallah M, Pamoukdjian F, Héraud A, Gapihan G, Walle AVD, Tran VN, Hamdan D, Allayous C, Battistella M, Van Glabeke E, Lim KW, Leboeuf C, Roger S, Falgarone G, Phan AT, Bousquet G. PROM2 overexpression induces metastatic potential through epithelial-to-mesenchymal transition and ferroptosis resistance in human cancers. Clin Transl Med 2024; 14:e1632. [PMID: 38515278 PMCID: PMC10958126 DOI: 10.1002/ctm2.1632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 02/28/2024] [Accepted: 03/04/2024] [Indexed: 03/23/2024] Open
Abstract
INTRODUCTION Despite considerable therapeutic advances in the last 20 years, metastatic cancers remain a major cause of death. We previously identified prominin-2 (PROM2) as a biomarker predictive of distant metastases and decreased survival, thus providing a promising bio-target. In this translational study, we set out to decipher the biological roles of PROM2 during the metastatic process and resistance to cell death, in particular for metastatic melanoma. METHODS AND RESULTS Methods and results: We demonstrated that PROM2 overexpression was closely linked to an increased metastatic potential through the increase of epithelial-to-mesenchymal transition (EMT) marker expression and ferroptosis resistance. This was also found in renal cell carcinoma and triple negative breast cancer patient-derived xenograft models. Using an oligonucleotide anti-sense anti-PROM2, we efficaciously decreased PROM2 expression and prevented metastases in melanoma xenografts. We also demonstrated that PROM2 was implicated in an aggravation loop, contributing to increase the metastatic burden both in murine metastatic models and in patients with metastatic melanoma. The metastatic burden is closely linked to PROM2 expression through the expression of EMT markers and ferroptosis cell death resistance in a deterioration loop. CONCLUSION Our results open the way for further studies using PROM2 as a bio-target in resort situations in human metastatic melanoma and also in other cancer types.
Collapse
Affiliation(s)
- Justine Paris
- Université Paris Cité, INSERM, UMR_S942 MASCOTParisFrance
| | - Claire Wilhelm
- Laboratoire Physico Chimie Curie, Institut Curie, CNRSPSL Research UniversityParisFrance
| | - Celeste Lebbé
- Université Paris Cité, INSERMParisFrance
- APHP, Dermatolo‐OncologyHôpital Saint LouisParisFrance
| | - Mohammed Elmallah
- Inserm U1327 ISCHEMIAUniversité de Tours, Faculté de MédecineToursFrance
| | - Frédéric Pamoukdjian
- Université Paris Cité, INSERM, UMR_S942 MASCOTParisFrance
- APHP, Hôpital Avicenne, Médecine GériatriqueBobignyFrance
- Université Sorbonne Paris NordVilletaneuseFrance
| | - Audrey Héraud
- Inserm U1327 ISCHEMIAUniversité de Tours, Faculté de MédecineToursFrance
| | | | - Aurore Van De Walle
- Laboratoire Physico Chimie Curie, Institut Curie, CNRSPSL Research UniversityParisFrance
| | - Van Nhan Tran
- School of Physical and Mathematical SciencesNanyang Technological UniversitySingaporeSingapore
| | - Diaddin Hamdan
- Université Paris Cité, INSERM, UMR_S942 MASCOTParisFrance
- Hôpital La Porte Verte, CancérologieVersaillesFrance
| | - Clara Allayous
- Université Paris Cité, INSERMParisFrance
- APHP, Dermatolo‐OncologyHôpital Saint LouisParisFrance
| | - Maxime Battistella
- Université Paris Cité, INSERMParisFrance
- Pathology DepartmentAPHP, Hôpital Saint LouisParisFrance
| | - Emmanuel Van Glabeke
- Fédération d'Urologie de Seine‐Saint‐Denis, CHI Robert BallangéAulnay‐sous‐BoisFrance
| | - Kah Wai Lim
- School of Physical and Mathematical SciencesNanyang Technological UniversitySingaporeSingapore
| | | | - Sébastien Roger
- Inserm U1327 ISCHEMIAUniversité de Tours, Faculté de MédecineToursFrance
| | - Géraldine Falgarone
- Université Paris Cité, INSERM, UMR_S942 MASCOTParisFrance
- APHP, Hôpital Avicenne, Médecine GériatriqueBobignyFrance
- APHPHôpital Avicenne, Unité de Médecine Ambulatoire (UMA)BobignyFrance
| | - Anh Tuan Phan
- Université Sorbonne Paris NordVilletaneuseFrance
- NTU Institute of Structural BiologyNanyang Technological UniversitySingaporeSingapore
| | - Guilhem Bousquet
- Université Paris Cité, INSERM, UMR_S942 MASCOTParisFrance
- APHP, Hôpital Avicenne, Médecine GériatriqueBobignyFrance
- APHPHôpital Avicenne, Oncologie médicalBobignyFrance
| |
Collapse
|
13
|
Stammler R, Ta VA, Cohen E, Ram-Wolff C, Bozonnat A, Battesti G, Louveau B, Mourah S, Battistella M, Moins-Teisserenc H, de Masson A. Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma. Br J Dermatol 2024:ljae085. [PMID: 38390970 DOI: 10.1093/bjd/ljae085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2024] [Revised: 02/02/2024] [Accepted: 02/21/2024] [Indexed: 02/24/2024]
Abstract
We report three patients with Sezary syndrome who had previously been successfully treated with mogamulizumab and then failed after a second course with the same treatment despite positive CCR4 expression at mogamulizumab second initiation.
This suggests that secondary resistance of blood disease to mogamulizumab may be independent on target expression.
Collapse
Affiliation(s)
- Romain Stammler
- Department of Dermatology, Saint Louis hospital, AP-HP, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Van Anh Ta
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
| | - Elisabeth Cohen
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
| | | | - Alizée Bozonnat
- Department of Dermatology, Saint Louis hospital, AP-HP, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
| | - Gilles Battesti
- Department of Dermatology, Saint Louis hospital, AP-HP, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
| | - Baptiste Louveau
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Department of Pharmacogenomics and Tumor Genomics, Saint Louis hospital, AP-HP, Paris, France
| | - Samia Mourah
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Department of Pharmacogenomics and Tumor Genomics, Saint Louis hospital, AP-HP, Paris, France
| | - Maxime Battistella
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Pathology Department, Saint Louis Hospital, AP-HP, Paris, France
| | - Hélène Moins-Teisserenc
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Haematology Laboratory, Saint Louis Hospital, AP-HP, Paris, France
| | - Adèle de Masson
- Department of Dermatology, Saint Louis hospital, AP-HP, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
14
|
Hamdan D, Gardair C, Pamoukdjian F, Peraldi Gardin MN, Nakouri I, Leboeuf C, Janin A, Lebbé C, Battistella M, Bousquet G. A Sub-Group of Kidney-Transplant Recipients with Highly Aggressive Squamous Cell Carcinoma Expressing Phosphorylated Serine392p53. Int J Mol Sci 2024; 25:1147. [PMID: 38256221 PMCID: PMC10816400 DOI: 10.3390/ijms25021147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 01/09/2024] [Accepted: 01/11/2024] [Indexed: 01/24/2024] Open
Abstract
Cutaneous squamous cell carcinomas in kidney-transplant recipients are frequent, with an increasing incidence linked to long immunosuppression durations and exposure to ultraviolet radiation. p53 is at the cornerstone of ultraviolet-induced DNA damage, but the role of p53 post-translational modifications in this context is not yet deciphered. Here, we investigated the phosphorylation status of p53 at Serine 392 in 25 cutaneous squamous cell carcinomas in kidney-transplant recipients, compared with 22 non-transplanted patients. Cutaneous squamous cell carcinomas in transplanted patients occurred after a median period of 19 years of immunosuppression, with a median number of 15 cutaneous squamous cell carcinomas and more aggressive histological and clinical characteristics. There was no significant difference between Ki67, p53, and pSer392p53 expression in the two groups. Using principal component analysis, we identified a cluster of exclusively transplanted patients with a median of 23 years of immunosuppression duration, significantly more aggressive biological characteristics, and higher pSer392p53 expression. pSer392p53 was expressed in the whole tumor, suggesting an early carcinogenic event in the course of prolonged immunosuppression. This high, diffuse pSer392p53 expression, corresponding to a high level of DNA damage, might be useful to identify aggressive cutaneous squamous cell carcinomas in kidney-transplant recipients to treat them more aggressively.
Collapse
Affiliation(s)
- Diaddin Hamdan
- Faculté de Santé, Site Lariboisière, Institut National de la Santé et de la Recherche Médicale INSERM, Unité Mixte de Recherche UMR_S942 MASCOT, Université Paris-Cité, F-75006 Paris, France
- Medical Oncology Department, Hôpital La Porte Verte, F-78000 Versailles, France
| | - Charlotte Gardair
- Faculté de Santé, Site Lariboisière, Institut National de la Santé et de la Recherche Médicale INSERM, Unité Mixte de Recherche UMR_S942 MASCOT, Université Paris-Cité, F-75006 Paris, France
| | - Frédéric Pamoukdjian
- Faculté de Santé, Site Lariboisière, Institut National de la Santé et de la Recherche Médicale INSERM, Unité Mixte de Recherche UMR_S942 MASCOT, Université Paris-Cité, F-75006 Paris, France
- UFR Santé Médecine et Biologie Humaine, Campus Bobigny, Université Sorbonne Paris Nord, F-93439 Villetaneuse, France
- Geriatric Medicine Department, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, F-93000 Bobigny, France
| | - Marie-Noëlle Peraldi Gardin
- Nephrology-Renal Transplantation Department, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, F-75015 Paris, France
| | - Inès Nakouri
- Faculté de Santé, Assistance Publique-Hôpitaux de Paris Dermato-Oncology, Cancer Institute APHP. Nord Paris Cité, Institut National de la Santé et de la Recherche Médicale INSERM Unité U976, Saint Louis Hospital, Université Paris-Cite, F-75010 Paris, France
| | - Christophe Leboeuf
- Faculté de Santé, Site Lariboisière, Institut National de la Santé et de la Recherche Médicale INSERM, Unité Mixte de Recherche UMR_S942 MASCOT, Université Paris-Cité, F-75006 Paris, France
| | - Anne Janin
- Faculté de Santé, Site Lariboisière, Institut National de la Santé et de la Recherche Médicale INSERM, Unité Mixte de Recherche UMR_S942 MASCOT, Université Paris-Cité, F-75006 Paris, France
| | - Céleste Lebbé
- Faculté de Santé, Assistance Publique-Hôpitaux de Paris Dermato-Oncology, Cancer Institute APHP. Nord Paris Cité, Institut National de la Santé et de la Recherche Médicale INSERM Unité U976, Saint Louis Hospital, Université Paris-Cite, F-75010 Paris, France
| | - Maxime Battistella
- Department of Pathology, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Faculté de Santé, Cancer Institute APHP. Nord Paris Cité, Institut National de la Santé et de la Recherche Médicale INSERM Unité U976, Université Paris-Cite, F-75010 Paris, France
| | - Guilhem Bousquet
- Faculté de Santé, Site Lariboisière, Institut National de la Santé et de la Recherche Médicale INSERM, Unité Mixte de Recherche UMR_S942 MASCOT, Université Paris-Cité, F-75006 Paris, France
- UFR Santé Médecine et Biologie Humaine, Campus Bobigny, Université Sorbonne Paris Nord, F-93439 Villetaneuse, France
- Medical Oncology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, F-93000 Bobigny, France
| |
Collapse
|
15
|
Kervarrec T, Pissaloux D, Tirode F, de la Fouchardière A, Sohier P, Frouin E, Hamard A, Houben R, Schrama D, Barlier A, Cribier B, Battistella M, Macagno N. Gene fusions in poroma, porocarcinoma and related adnexal skin tumours: An update. Histopathology 2024; 84:266-278. [PMID: 37609771 DOI: 10.1111/his.15023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Revised: 07/24/2023] [Accepted: 07/25/2023] [Indexed: 08/24/2023]
Abstract
Poroma is a benign sweat gland tumour showing morphological features recapitulating the superficial portion of the eccrine sweat coil. A subset of poromas may transform into porocarcinoma, its malignant counterpart. Poroma and porocarcinoma are characterised by recurrent gene fusions involving YAP1, a transcriptional co-activator, which is controlled by the Hippo signalling pathway. The fusion genes frequently involve MAML2 and NUTM1, which are also rearranged in other cutaneous and extracutaneous neoplasms. We aimed to review the clinical, morphological and molecular features of this category of adnexal neoplasms with a special focus upon emerging differential diagnoses, and discuss how their systematic molecular characterisation may contribute to a standardisation of diagnosis, more accurate classification and, ultimately, refinement of their prognosis and therapeutic modalities.
Collapse
Affiliation(s)
- Thibault Kervarrec
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France
- Department of Pathology, University Hospital of Tours, Tours, France
- 'Biologie des infections à polyomavirus' Team, UMR1282 INRAE, University of Tours, Tours, France
| | | | - Franck Tirode
- Department of Biopathology, Center Léon Bérard, Lyon, France
- Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée, University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France
| | - Arnaud de la Fouchardière
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France
- Department of Biopathology, Center Léon Bérard, Lyon, France
- Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée, University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France
| | - Pierre Sohier
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France
- Department of Pathology, Hôpital Cochin, AP-HP, AP-HP Centre - Université Paris Cité, Paris, France
- Faculté de Médecine, University Paris Cité, Paris, France
| | - Eric Frouin
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France
- Department of Pathology, University Hospital of Poitiers, University of Poitiers, LITEC, Poitiers, France
| | - Aymeric Hamard
- Department of Pathology, University Hospital of Tours, Tours, France
| | - Roland Houben
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
| | - David Schrama
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
| | - Anne Barlier
- Aix-Marseille Univ, INSERM, MMG, U1251, Marmara Institute, Marseille, France
- Laboratory of Molecular Biology, La Conception Hospital, Marseille, France
| | - Bernard Cribier
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France
- Clinique Dermatologique, Hôpital Civil, Hôpitaux Universitaires, Université de Strasbourg, Strasbourg, France
| | - Maxime Battistella
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France
- Department of Pathology, Hospital Saint-Louis, AP-HP, Université Paris Cité, INSERM U976, Paris, France
| | - Nicolas Macagno
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France
- Aix-Marseille Univ, INSERM, MMG, U1251, Marmara Institute, Marseille, France
- Department of Pathology, APHM, Timone University Hospital, Marseille, France
| |
Collapse
|
16
|
Cohen E, Bozonnat A, Battistella M, Calvani J, Vignon-Pennamen MD, Rivet J, Moins-Teisserenc H, Ta VA, Ram-Wolff C, Bouaziz JD, Mahevas T, Bagot M, Mourah S, Louveau B, Sicre de Fontbrune F, Peffault de Latour R, de Masson A, Battesti G. Severe relapses of cutaneous T-cell lymphoma after treatment of chronic graft-versus-host disease with ruxolitinib. J Eur Acad Dermatol Venereol 2024; 38:e32-e34. [PMID: 37561935 DOI: 10.1111/jdv.19408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 08/03/2023] [Indexed: 08/12/2023]
Affiliation(s)
- Elisabeth Cohen
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
| | - Alizée Bozonnat
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
| | - Maxime Battistella
- Université Paris Cité, Paris, France
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Julien Calvani
- Université Paris Cité, Paris, France
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | | | - Jacqueline Rivet
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France
| | - Hélène Moins-Teisserenc
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
- Université Paris Cité, Paris, France
- Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France
| | - Van-Anh Ta
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
| | | | - Jean-David Bouaziz
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Thibault Mahevas
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Martine Bagot
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Samia Mourah
- Université Paris Cité, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | - Baptiste Louveau
- Université Paris Cité, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
- Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | | | | | - Adèle de Masson
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France
| | - Gilles Battesti
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
17
|
Delyon J, Schmauch B, Jacob Y, Battistella M, Lebbé C. Letter to the Editor re: Observational study investigating the level of support from a convolutional neural network in face and scalp lesions deemed diagnostically 'unclear' by dermatologists. Eur J Cancer 2023; 195:113394. [PMID: 37891064 DOI: 10.1016/j.ejca.2023.113394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Accepted: 09/26/2023] [Indexed: 10/29/2023]
Affiliation(s)
- Julie Delyon
- Department of Dermato-Oncology, AP-HP Saint-Louis Hospital, DMU ICARE, Université Paris Cité, INSERM U976 HIPI Team 1, F-75010 Paris, France.
| | | | - Yannick Jacob
- Innovation and Data Unit, IT Department, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Maxime Battistella
- Department of Pathology, AP-HP Saint-Louis Hospital, Université Paris Cité, INSERM U976 HIPI Team 1, F-75010 Paris, France
| | - Céleste Lebbé
- Department of Dermato-Oncology, AP-HP Saint-Louis Hospital, DMU ICARE, Université Paris Cité, INSERM U976 HIPI Team 1, F-75010 Paris, France
| |
Collapse
|
18
|
Calugareanu A, Specque F, Demouche S, Grolleau C, Dobos G, Merandet M, Bergerat D, Peltier S, Jachiet M, Cassius C, Mahevas T, Saussine A, How-Kit A, Onifarasoaniaina R, Serror K, Bohec M, Baulande S, Lepelletier C, Mrad M, Charvet E, Masson AD, Boccara D, Battistella M, Buanec HL, Bouaziz JD. Transcriptomic Landscape of Prurigo Nodularis Lesional Skin CD3+ T Cells Using Single-Cell RNA Sequencing. J Invest Dermatol 2023; 143:2525-2529.e5. [PMID: 37263486 DOI: 10.1016/j.jid.2023.05.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Revised: 04/28/2023] [Accepted: 05/04/2023] [Indexed: 06/03/2023]
Affiliation(s)
- Andreea Calugareanu
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Florian Specque
- Clinical Research and Bioinformatics Unit, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Sarah Demouche
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Chloe Grolleau
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Gabor Dobos
- Skin Tumor Centre Charité (HTCC), Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | | | | | | | - Marie Jachiet
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Charles Cassius
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Thibault Mahevas
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anne Saussine
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | | | - Kevin Serror
- INSERM U976, Hôpital Saint-Louis, Paris, France; Department of Plastic Surgery and Burn Unit, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Mylène Bohec
- Institut Curie Genomics of Excellence (ICGex) Platform, Paris, France
| | - Sylvain Baulande
- Institut Curie Genomics of Excellence (ICGex) Platform, Paris, France
| | - Clemence Lepelletier
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marc Mrad
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Estelle Charvet
- Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Adèle de Masson
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - David Boccara
- INSERM U976, Hôpital Saint-Louis, Paris, France; Institut Cochin, INSERM U1016, CNRS UMR8104, Université de Paris, Paris, France; Université de Paris, Paris, France
| | - Maxime Battistella
- INSERM U976, Hôpital Saint-Louis, Paris, France; Université de Paris, Paris, France; Pathology department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | - Jean-David Bouaziz
- INSERM U976, Hôpital Saint-Louis, Paris, France; Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
| |
Collapse
|
19
|
Chircop I, Guindolet D, Battistella M, Martinez-Vinson C, Bourrat E. Paradoxical inflammatory blepharitis in a patient with Crohn's disease. J AAPOS 2023; 27:377-378. [PMID: 37871794 DOI: 10.1016/j.jaapos.2023.08.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 08/24/2023] [Accepted: 08/28/2023] [Indexed: 10/25/2023]
Abstract
We report the case of a 15-year-old boy with severe inflammatory blepharitis who was being treated with a TNFα inhibitor for Crohn's disease (CD). This case shows the potential utility of a skin biopsy in distinguishing metastatic CD associated with granulomatous blepharitis from a paradoxical blepharitis induced by anti-TNFα. It also demonstrates that ustekinumab can be considered in patients with CD who cannot tolerate TNFα inhibitors because of cutaneous paradoxical reactions.
Collapse
Affiliation(s)
- Inès Chircop
- Department of Dermatology, Hôpital Edouard Herriot, Lyon, France.
| | - Damien Guindolet
- Department of Ophthalmology, Fondation A. de Rothschild, AP-HP, Paris, France
| | - Maxime Battistella
- Department of Pathology, Hôpital Saint-Louis, AP-HP, Paris, France; Inserm HIPI U976, team 1: onco-dermatology and therapies
| | | | - Emmanuelle Bourrat
- Department of General Pediatrics, Infectious Disease and Internal Medicine, Hôpital Robert Debré, AP-HP, Paris, France
| |
Collapse
|
20
|
Legrand M, Pissaloux D, Tirode F, Tallet A, Collin C, Chantreau PL, Berthon P, Jullie ML, Sohier P, Calonje E, Luzar B, Moulonguet I, Goto K, Cokelaere K, Lamant L, Balme B, Deschamps L, Macagno N, Cribier B, Battistella M, de la Fouchardière A, Kervarrec T. SSTR2A is a diagnostic marker of trichogerminoma. J Eur Acad Dermatol Venereol 2023; 37:e1344-e1347. [PMID: 37421254 DOI: 10.1111/jdv.19319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Accepted: 06/27/2023] [Indexed: 07/10/2023]
Affiliation(s)
- Mélanie Legrand
- Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France
| | - Daniel Pissaloux
- Department of Biopathology, Center Léon Bérard, Lyon, France
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Franck Tirode
- Department of Biopathology, Center Léon Bérard, Lyon, France
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Anne Tallet
- Platform of Somatic Tumor Molecular Genetics, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France
| | - Christine Collin
- Platform of Somatic Tumor Molecular Genetics, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France
| | - Paul-Louis Chantreau
- Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France
| | - Patricia Berthon
- "Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, Tours, France
| | - Marie-Laure Jullie
- French Network of Rare Skin Cancers, CARADERM, France
- Department of Pathology, Hôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France, CARADERM network
| | - Pierre Sohier
- French Network of Rare Skin Cancers, CARADERM, France
- Department of Pathology, Hôpital Cochin, AP-HP, AP-HP.Centre - Faculté de Médecine, University Paris Cité, Paris, France
| | - Eduardo Calonje
- Department of Dermatopathology, St John's Institute of Dermatology, St Thomas's Hospital, London, UK
| | - Boštjan Luzar
- Institute of Pathology, Medical Faculty University of Ljubljana, Ljubljana, Slovenia
| | - Isabelle Moulonguet
- Department of Pathology, APHP Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - Keisuke Goto
- Department of Pathology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan
- Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Japan
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan
- Department of Dermatology, Hyogo Cancer Center, Akashi, Japan
| | | | - Laurence Lamant
- Department of Pathology, CHU Toulouse, Institut Universitaire du Cancer Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Brigitte Balme
- Department of Pathology, Centre Hospitalier Universitaire de Lyon, Lyon, France
| | - Lydia Deschamps
- Department of Pathology, APHP Bichat Hospital, Paris, France
| | - Nicolas Macagno
- French Network of Rare Skin Cancers, CARADERM, France
- Department of Pathology, Timone University Hospital, Marseille, France
| | - Bernard Cribier
- French Network of Rare Skin Cancers, CARADERM, France
- Dermatology Clinic, Hôpitaux Universitaires & Université de Strasbourg, Hôpital Civil, Strasbourg, France
| | - Maxime Battistella
- French Network of Rare Skin Cancers, CARADERM, France
- Department of Pathology, APHP Hôpital Saint Louis, Université Paris Cité, Paris, France
| | - Arnaud de la Fouchardière
- Department of Biopathology, Center Léon Bérard, Lyon, France
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Thibault Kervarrec
- Department of Pathology, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France
- "Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, Tours, France
- French Network of Rare Skin Cancers, CARADERM, France
| |
Collapse
|
21
|
Bogiatzi S, Estenaga A, Louveau B, Osio A, Deschamps L, Mourah S, Poirot B, Lehmann-Che J, Cribier B, Battistella M. Microsecretory adenocarcinoma of the skin, a novel type of sweat gland carcinoma: Report of three additional cases. J Cutan Pathol 2023; 50:897-902. [PMID: 36790018 DOI: 10.1111/cup.14408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 02/07/2023] [Accepted: 02/08/2023] [Indexed: 02/16/2023]
Abstract
Microsecretory adenocarcinoma (MSA) is a newly described salivary gland tumor harboring a characteristic balanced chromosomal translocation resulting in MEF2C::SS18 gene fusion. Six primary cutaneous MSA cases have been recently described. We report three additional cases confirming the relevance of this recently identified entity of primary cutaneous adnexal tumor. Three patients aged 53-, 64- and 78-year-old were retrospectively diagnosed with MSA of the skin (MSAS) as consultation cases of the CARADERM (CAncers RAres DERMatologiques) national network. The clinical presentation was an indolent nodule on the upper extremities. There was no history of salivary gland tumor. Histopathologically, the tumors presented as dermal nodular proliferation with slightly infiltrative borders, composed of cribriform and microcystic structures with abundant myxoid intraluminal secretion embedded in a fibromyxoid stroma. They diffusely expressed cytokeratin 8 and SOX10, focally p63 and heterogeneously smooth muscle actin. All tumors harbored the MEF2C::SS18 gene fusion. A complete surgical excision was performed. No local recurrence or distant metastases were observed so far (follow-up: 17, 38, and 45 months). MSAS is the cutaneous homologue of MSA of the salivary gland, a low-grade adnexal neoplasm whose prognosis seems to be excellent once the complete removal of the tumor is assured.
Collapse
Affiliation(s)
- Sofia Bogiatzi
- Pathology Department, Saint-Louis Hospital, Paris, France
| | | | - Baptiste Louveau
- Solid Tumor Genomics Department, Saint-Louis Hospital, Paris, France
| | - Amélie Osio
- Pathology Department, Saint-Louis Hospital, Paris, France
| | | | - Samia Mourah
- Solid Tumor Genomics Department, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Paris, France
| | - Brigitte Poirot
- Solid Tumor Genomics Department, Saint-Louis Hospital, Paris, France
| | - Jacqueline Lehmann-Che
- Solid Tumor Genomics Department, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Paris, France
| | - Bernard Cribier
- Dermatopathology Unit, Clinique Dermatologique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Maxime Battistella
- Pathology Department, Saint-Louis Hospital, Paris, France
- Université Paris Cité, Paris, France
- INSERM U976, Paris, France
| |
Collapse
|
22
|
Calugareanu A, de Masson A, Battistella M, Michel L, Ram-Wolff C, Bouaziz JD, Peltier S, Bensussan A, Bagot M, Dobos G. Exploring the Nonlymphocytic Cutaneous Microenvironment in Advanced Cutaneous T-Cell Lymphomas using Single-Cell RNA Sequencing. J Invest Dermatol 2023; 143:2078-2082.e4. [PMID: 37100194 DOI: 10.1016/j.jid.2022.07.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 06/29/2022] [Accepted: 07/23/2022] [Indexed: 04/28/2023]
Affiliation(s)
- Andreea Calugareanu
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France; UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Adèle de Masson
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France; UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Maxime Battistella
- UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France; Pathology Department, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France
| | - Laurence Michel
- UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France
| | - Jean-David Bouaziz
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France; UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Sandy Peltier
- UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Armand Bensussan
- UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Martine Bagot
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France; UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France
| | - Gabor Dobos
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Paris, France; UMR-976, HIPI (Human Immunology, Pathophysiology, Immunotherapy), INSERM, Paris, France; Université de Paris, Paris, France; Department of Dermatology, Venereology, and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
| |
Collapse
|
23
|
Decroos A, Cheminant M, Bruneau J, Carras S, Parinet V, Pelletier L, Lacroix L, Martin N, Giustiniani J, Lhermitte L, Asnafi V, Battistella M, Lemonnier F, De Leval L, Sicard H, Bonnafous C, Gauthier L, Genestier L, Caruso S, Gaulard P, Hermine O, Ortonne N. KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma. Haematologica 2023; 108:2830-2836. [PMID: 37165836 PMCID: PMC10542838 DOI: 10.3324/haematol.2022.282220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Accepted: 05/03/2023] [Indexed: 05/12/2023] Open
Affiliation(s)
- Amandine Decroos
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil
| | - Morgane Cheminant
- Université de Paris, Institut Imagine, Laboratory of Hematological Disorders, INSERM UMR1163, F-75015, Paris, France; Necker-Enfants Malades University Medical Center, AP-HP Clinical Hematology, F-75015, Paris
| | - Julie Bruneau
- Université de Paris, Institut Imagine, Laboratory of Hematological Disorders, INSERM UMR1163, F-75015, Paris, France; Necker-Enfants Malades University Medical Center, AP-HP, Department of Pathology, F-75015, Paris
| | - Sylvain Carras
- Institute for Advanced Biosciences, "Translational Epigenetics" team, UMR 1209/CNRS 5309, La Tronche
| | - Vincent Parinet
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil
| | - Laura Pelletier
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil
| | - Laetitia Lacroix
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Université de Paris, Institut Imagine, Laboratory of Hematological Disorders, INSERM UMR1163, F-75015, Paris
| | - Nadine Martin
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil
| | - Jérôme Giustiniani
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil
| | - Ludovic Lhermitte
- Université de Paris, Institut Necker-Enfants Malades, Laboratory of Onco-Hematology, APHP, INSERM UMR 1151, Paris
| | - Vahid Asnafi
- Université de Paris, Institut Necker-Enfants Malades, Laboratory of Onco-Hematology, APHP, INSERM UMR 1151, Paris
| | - Maxime Battistella
- Université Paris Cité ; INSERM U976 ; AP-HP, Department of Pathology, Saint-Louis hospital, F-75010 Paris
| | - François Lemonnier
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Henri Mondor hospital, Clinical Hematology, Unité Hémopathies Lymphoïdes, AP-HP, F-94010, Créteil
| | - Laurence De Leval
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University
| | | | | | | | - Laurent Genestier
- Claude Bernard Lyon 1 University, ENS de Lyon, CNRS, UMR5308, INSERM U1111, CIRI, Centre International de Recherche en Infectiologie, Lymphoma Immunobiology Team (LIB), Equipe Labellisée Ligue Contre le Cancer, F-69007, Lyon, France; Hospices Civils de Lyon, Lyon
| | - Stefano Caruso
- Henri Mondor hospital, AP-HP, Department of Pathology, F-94010, Créteil
| | - Philippe Gaulard
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Henri Mondor hospital, AP-HP, Department of Pathology, F-94010, Créteil
| | - Olivier Hermine
- Université de Paris, Institut Imagine, Laboratory of Hematological Disorders, INSERM UMR1163, F-75015, Paris, France; Necker-Enfants Malades University Medical Center, AP-HP Clinical Hematology, F-75015, Paris
| | - Nicolas Ortonne
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Henri Mondor hospital, AP-HP, Department of Pathology, F-94010, Créteil.
| |
Collapse
|
24
|
Kervarrec T, Tallet A, Macagno N, de la Fouchardière A, Pissaloux D, Tirode F, Bravo IG, Nicolas A, Baulande S, Sohier P, Balme B, Osio A, Jullie ML, Moulonguet I, Bonsang B, Tournier E, Herfs M, Frouin E, Zidan A, Calonje E, Berthon P, Touzé A, Seris A, Mortier L, Jouary T, Cribier B, Battistella M. Sweat Gland Tumors Arising on Acral Sites: A Molecular Survey. Am J Surg Pathol 2023; 47:1096-1107. [PMID: 37505808 DOI: 10.1097/pas.0000000000002098] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/29/2023]
Abstract
Recurrent oncogenic drivers have been identified in a variety of sweat gland tumors. Recently, integration of human papillomavirus type 42 (HPV42) has been reported in digital papillary adenocarcinoma (DPA). The main objectives of the present study were (i) to provide an overview of the prevalence of previously identified oncogenic drivers in acral sweat gland tumors and (ii) to genetically characterize tumors in which no recurrent genetic alteration has been identified yet. Cases of acral sweat gland tumors were identified from the database of the French network CARADERM. After histologic review, the presence of previously identified genetic alterations was investigated in the entire cohort (n=79) using a combination of immunohistochemistry and targeted DNA and RNA sequencing. Tumor entities with no recurrent genetic alterations were submitted to whole-transcriptome sequencing. CRTC1::MAML2 fusion was identified in cases of hidradenoma and hidradenocarcinoma (n=9/12 and n=9/12). A p.V600E mutation of BRAF was observed in all cases of tubular adenoma (n=4). YAP1:MAML2 and YAP1::NUTM1 fusions were observed in poroid tumors (n=15/25). ETV6::NTRK3 and TRPS1::PLAG1 fusion transcripts were identified in secretory carcinoma (n=1/1) and cutaneous mixed tumors (n=3/4), respectively. The HPV42 genome was detected in most cases of DPA (n=10/11) and in 1 adnexal adenocarcinoma not otherwise specified. Finally, whole-transcriptome analysis revealed BRD3::NUTM1 or NSD3::NUTM1 fusions in 2 cases of NUT adnexal carcinoma and NCOA4::RET and CCDC6::RET fusion transcripts in 2 cystadenoma/hidrocystoma-like tumors. Our study confirms distinctive cytogenetic abnormalities in a wide number of acral adnexal neoplasms and supports the use of molecular analysis as a valuable aid in the diagnosis of these rare and often difficult to diagnose group of neoplasms.
Collapse
Affiliation(s)
- Thibault Kervarrec
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, University Hospital Center of Tours
- "Biologie des infections polyomavirus" Team, UMR INRA ISP1282, University of Tours
| | - Anne Tallet
- Platform of Solid Tumor Molecular Genetics, University Hospital Center of Tours, Tours
| | - Nicolas Macagno
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, APHM, Timone University Hospital
- Aix Marseille University, INSERM, MMG, UMR1251, Marmara Institute, Marseille
| | - Arnaud de la Fouchardière
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Biopathology, Center Léon Bérard
- University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer
| | - Daniel Pissaloux
- Department of Biopathology, Center Léon Bérard
- University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer
| | - Franck Tirode
- University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer
| | - Ignacio G Bravo
- French National Center for Scientific Research (CNRS), Laboratory MIVEGEC (CNRS IRD Univ Montpellier), Montpellier
| | - Alain Nicolas
- Institut Curie, PSL Research University, CNRS UMR3244
| | | | - Pierre Sohier
- CARADERM, French Network of Rare Cutaneous Cancer
- Faculté de Médecine Paris Centre Santé, University of Paris
- Department of Pathology, Cochin Hospital, AP-HP, AP-HP Centre-Université de Paris
| | - Brigitte Balme
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, University Hospital Center of Lyon-Sud, Hospices Civils de Lyon, Lyon
| | - Amélie Osio
- CARADERM, French Network of Rare Cutaneous Cancer
- National Center of Dermatopathology, Paris-la Roquette, Ivry
| | - Marie-Laure Jullie
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, University Hospital Center of Bordeaux, Pessac
| | | | - Benjamin Bonsang
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, Hôpital Ambroise Pare, AP-HP
| | - Emilie Tournier
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, CHU Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole
- Université Toulouse III Paul Sabatier, Toulouse
| | - Michael Herfs
- Laboratory of Experimental Pathology, GIGA-Cancer, University of Liège, Liège, Belgium
| | - Eric Frouin
- Department of Pathology, University Hospital Center of Poitiers, LITEC, UR 15560, University of Poitiers, Poitiers
| | - Anoud Zidan
- Dermatopathology Laboratory, St John's Institute of Dermatology, St Thomas' Hospital, London, UK
| | - Eduardo Calonje
- Dermatopathology Laboratory, St John's Institute of Dermatology, St Thomas' Hospital, London, UK
| | - Patricia Berthon
- "Biologie des infections polyomavirus" Team, UMR INRA ISP1282, University of Tours
| | - Antoine Touzé
- "Biologie des infections polyomavirus" Team, UMR INRA ISP1282, University of Tours
| | - Alice Seris
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Dermatology, Hospital Center of Pau, Pau
| | - Laurent Mortier
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Dermatology, University Hospital Center of Lille, Lille
| | - Thomas Jouary
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Dermatology, Hospital Center of Pau, Pau
| | - Bernard Cribier
- CARADERM, French Network of Rare Cutaneous Cancer
- Clinique Dermatologique, Hôpitaux Universitaires & Université de Strasbourg, Hôpital Civil, Strasbourg, France
| | - Maxime Battistella
- CARADERM, French Network of Rare Cutaneous Cancer
- Department of Pathology, Hopital Saint Louis, AP-HP Universite ́ Paris 7, Paris
| |
Collapse
|
25
|
Kervarrec T, Imbeaud S, Veyer D, Pere H, Puech J, Pekár-Lukacs A, Markiewicz D, Coutts M, Tallet A, Collin C, Berthon P, Bravo IG, Seris A, Jouary T, Macagno N, Touzé A, Cribier B, Battistella M, Calonje E. Digital Papillary Adenocarcinoma in Nonacral Skin: Clinicopathologic and Genetic Characterization of 5 Cases. Am J Surg Pathol 2023; 47:1077-1084. [PMID: 37505796 DOI: 10.1097/pas.0000000000002096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/29/2023]
Abstract
Digital papillary adenocarcinoma (DPA) is a rare sweat gland neoplasm that has exceptionally been reported outside acral locations. Recently, human papillomavirus 42 was identified as the main oncogenic driver of DPA. Herein, we report 5 tumors arising in extra-acral locations predominantly in the female anogenital skin. Four patients were female and 1 patient was male. The mean age at the diagnosis time was 65 years (range: 55 to 82 y). Tumors were located on the vulva (n=3), perianal area (n=1), and forearm (n=1). Histologically, all tumors were lobular and mainly solid and composed of sheets of cells with rare focal papillae and frequent glandular structures in a "back-to-back" pattern and lined by atypical basophilic cells. Immunohistochemistry showed diffuse positivity for SOX10. Epithelial membrane antigen and carcinoembryonic antigen highlighted the luminal cells and staining for p63 and p40 revealed a consistent and continuous myoepithelial component around glandular structures. Follow-up was available in 3 cases (mean duration: 12 mo [range: 8 to 16 mo]). One patient developed local recurrence and 1 experienced regional lymph node metastases. HPV Capture Next-generation sequencing revealed the presence of the HPV42 genome in all samples. Viral reads distributions were compatible in the 5 cases with an episomal nature of the viral genome, with a recurrent deletion in the E1 and/or E2 open reading frames. In conclusion, this study demonstrates that digital DPA may rarely present in nonacral locations mainly in the female anogenital area, usually with a more solid pattern as compared with those cases presenting on the digits and it is also associated with HPV42.
Collapse
Affiliation(s)
- Thibault Kervarrec
- Department of Pathology
- Biologie des infections à polyomavirus" team, UMR INRAE ISP 1282, Université de Tours, Tours
- CARADERM Network
| | - Sandrine Imbeaud
- INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne Université
| | - David Veyer
- INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne Université
- Department of Virology, European Georges Pompidou Hospital, APHP, Université de Paris
| | - Helene Pere
- INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne Université
- Department of Virology, European Georges Pompidou Hospital, APHP, Université de Paris
| | - Julien Puech
- INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne Université
| | - Agnes Pekár-Lukacs
- Department of Oncology and Pathology, Lund University, Lund, Sweden
- Department of Dermatopathology, St John's Institute of Dermatology, St Thomas's Hospital, London
| | - Dorota Markiewicz
- Department of Dermatopathology, St John's Institute of Dermatology, St Thomas's Hospital, London
| | - Michael Coutts
- Department of Cellular Pathology, Maidstone Hospital, Kent, UK
| | - Anne Tallet
- Platform of Somatic Tumor Molecular Genetics, Université de Tours, Centre Hospitalier Universitaire de Tours
| | - Christine Collin
- Platform of Somatic Tumor Molecular Genetics, Université de Tours, Centre Hospitalier Universitaire de Tours
| | - Patricia Berthon
- Biologie des infections à polyomavirus" team, UMR INRAE ISP 1282, Université de Tours, Tours
| | - Ignacio G Bravo
- French National Center for Scientific Research (CNRS), Laboratory MIVEGEC (CNRS IRD Univ Montpellier), Montpellier
| | - Alice Seris
- CARADERM Network
- Department of Dermatology, Hospital Center of Pau, Pau
| | - Thomas Jouary
- CARADERM Network
- Department of Dermatology, Hospital Center of Pau, Pau
| | - Nicolas Macagno
- Department of Pathology, APHM, Timone University Hospital
- Aix-Marseille University, INSERM U1251, MMG, Marseille
| | - Antoine Touzé
- Biologie des infections à polyomavirus" team, UMR INRAE ISP 1282, Université de Tours, Tours
| | - Bernard Cribier
- Clinique dermatologique, Hôpitaux Universitaires & Université de Strasbourg, Hôpital Civil, Strasbourg, France
| | - Maxime Battistella
- Department of Pathology, APHP Hôpital Saint Louis, INSERM U976, Université Paris Cité7, Paris
| | - Eduardo Calonje
- Department of Dermatopathology, St John's Institute of Dermatology, St Thomas's Hospital, London
| |
Collapse
|
26
|
Sinson H, Karayan-Tapon L, Godet J, Rivet P, Alleyrat C, Battistella M, Pierron H, Morel F, Lecron JC, Favot L, Frouin E. Immunohistochemistry, Molecular Biology, and Clinical Scoring for the Detection of Muir-Torre Syndrome in Cutaneous Sebaceous Tumors: Which Strategy? Dermatology 2023; 239:889-897. [PMID: 37717564 DOI: 10.1159/000534126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Accepted: 09/08/2023] [Indexed: 09/19/2023] Open
Abstract
BACKGROUND Sebaceous neoplasms (SNs) always raise the possibility of an association with Muir-Torre syndrome (MTS) and permit to screen internal malignancies, colorectal and endometrial carcinomas, before they become symptomatic. Immunohistochemistry (IHC), molecular biology, and clinical examination are different approaches for detection of MTS. We conducted a retrospective analysis of non-selected SNs in order to determine the optimal tools to implement for MTS screening. METHODS Deficient MMR phenotype (dMMR) was determined by either IHC using antibodies directed to four mismatch repair (MMR) antigens on tissue microarray or molecular biology using pentaplex PCR. The Mayo Clinic risk score of MTS was calculated from medical records. Sensibility and specificity of each test for the detection of MTS were determined. RESULTS We included 107 patients, 8 with multiple SNs, for a total of 123 SNs (43 sebaceous adenomas, 19 sebaceomas, and 61 sebaceous carcinomas (SC)). Loss of at least one MMR protein was observed in 70.7% of tumors, while 48% had a microsatellite instable phenotype. Concordance between both techniques was 92.9%, with a 0.85 Cohen's kappa coefficient. Nineteen patients (20.2%) had a ≥2 points Mayo Clinic risk score, one having a pMMR SC. Among the 13 patients with confirmed MTS, 2 had a low Mayo Clinic risk score (1 point). IHC had the highest sensitivity for MTS screening (100%) with a specificity of 34.1%, while a >2-point Mayo Clinic risk score had a lower sensitivity (92%) but a higher specificity (89%). CONCLUSION To detect MTS in SN patients, the first-line Mayo Clinic risk score followed by IHC appears to be the most accurate strategy with lower cost for society. This strategy should be adapted to the medico-economic resources of each country.
Collapse
Affiliation(s)
- Hélinie Sinson
- Department of Pathology, University Hospital of Poitiers, Poitiers, France
| | - Lucie Karayan-Tapon
- ProDiCeT, University of Poitiers, Poitiers, France
- CHU De Poitiers, Department of Cancer Biology, Poitiers, France
| | - Julie Godet
- Department of Pathology, University Hospital of Poitiers, Poitiers, France
| | - Pierre Rivet
- ProDiCeT, University of Poitiers, Poitiers, France
- CHU De Poitiers, Department of Cancer Biology, Poitiers, France
| | - Camille Alleyrat
- Plateforme Méthodologie Biostatistiques, Data-Management, University Hospital of Poitiers, Poitiers, France
| | - Maxime Battistella
- Department of Pathology, Saint-Louis Hospital, AP-HP, Université Paris Cité, INSERM U976, Paris, France
| | - Hugo Pierron
- Department of Pathology, University Hospital of Poitiers, Poitiers, France
- CHU De Poitiers, Department of Cancer Biology, Poitiers, France
| | | | - Jean-Claude Lecron
- LITEC, University of Poitiers, Poitiers, France
- Department of Immunology and Inflammation, University Hospital of Poitiers, Poitiers, France
| | - Laure Favot
- LITEC, University of Poitiers, Poitiers, France
| | - Eric Frouin
- Department of Pathology, University Hospital of Poitiers, Poitiers, France
- LITEC, University of Poitiers, Poitiers, France
| |
Collapse
|
27
|
Kervarrec T, Sohier P, Pissaloux D, de la Fouchardiere A, Cribier B, Battistella M, Macagno N. Genetics of adnexal tumors: An update. Ann Dermatol Venereol 2023; 150:202-207. [PMID: 37270318 DOI: 10.1016/j.annder.2023.03.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Accepted: 03/07/2023] [Indexed: 06/05/2023]
Abstract
Cutaneous adnexal tumors form a vast heterogeneous group that include frequent entities that are mostly benign, as well as rare tumors that are occasionally malignant. In contrast to cutaneous tumors arising from the interfollicular epidermis that develop as a result of accumulation of UV-induced DNA damage (basal cell carcinoma, squamous cell carcinoma), the oncogenesis of adnexal tumors is related to a broad spectrum of genetic mechanisms (e.g., point mutation, fusion genes, viral integration, etc.). In this setting, specific and recurrent genetic alterations have been progressively reported, and these allow better classification of these entities. For certain of them, immunohistochemical tools are now available, enabling precise integrated histological and molecular diagnosis since certain entities are linked to well-defined alterations. In this context, we aim in this review to summarize the main molecular tools currently available for the classification of adnexal tumors.
Collapse
Affiliation(s)
- T Kervarrec
- CARADERM Network, Lille, France; Department of Pathology, University Hospital Center of Tours, Tours, France.
| | - P Sohier
- CARADERM Network, Lille, France; Department of Pathology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, AP-HP Centre - University of Paris Cité, Paris, France; Faculty of Medicine, University of Paris Cité, Paris, France
| | - D Pissaloux
- Department of Pathology, Centre Léon Bérard, Lyon, France
| | | | - B Cribier
- CARADERM Network, Lille, France; Dermatology Clinic, University Hospital of Strasbourg, Hôpital Civil, Strasbourg, France
| | - M Battistella
- CARADERM Network, Lille, France; Department of Pathology, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris, AP-HP Centre - Paris 7, Paris, France
| | - N Macagno
- CARADERM Network, Lille, France; Department of Pathology, AP-HM, University Hospital of la Timone, Marseille, France; University of Aix-Marseille, INSERM U1251, MMG, Marseille, France
| |
Collapse
|
28
|
Ranjbaryan M, Calvani J, Louveau B, Cuccuini W, Battesti G, Bozonnat A, Moins-Teisserenc H, Michonneau D, Bagot M, Ram-Wolff C, Dobos G, Mourah S, Battistella M, de Masson A. Graft-versus-lymphoma effect in skin after allogeneic hematopoietic stem cell transplantation for Sézary syndrome. Eur J Dermatol 2023; 33:439-440. [PMID: 37823502 DOI: 10.1684/ejd.2023.4522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/13/2023]
Affiliation(s)
- Merian Ranjbaryan
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Julien Calvani
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France, INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France
| | - Baptiste Louveau
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France, Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | - Wendy Cuccuini
- Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France
| | - Gilles Battesti
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Alizée Bozonnat
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Hélène Moins-Teisserenc
- Université Paris Cité, France, Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France, INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
| | - David Michonneau
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France, Department of Hematology and Bone Marrow Transplant, APHP, Saint-Louis Hospital, Paris, France
| | - Martine Bagot
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France, INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France
| | | | - Gabor Dobos
- Department of Dermatology, Charité University Hospital, Berlin, Germany
| | - Samia Mourah
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France, Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | - Maxime Battistella
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France, INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France
| | - Adèle de Masson
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France, INSERM U976, Institut de Recherche Saint-Louis, Paris, France, Université Paris Cité, France
| |
Collapse
|
29
|
Ta VA, Battistella M, Zhao LP, Dobos G, Ram-Wolff C, Madelaine I, Bories JC, Tournilhac O, Rouanet J, Veyrat-Masson R, Bouaziz JD, Marie-Cardine A, Bagot M, Bensussan A, Moins-Teisserenc H, De Masson A. CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas. J Invest Dermatol 2023; 143:1329-1332.e3. [PMID: 36716922 DOI: 10.1016/j.jid.2023.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Accepted: 01/09/2023] [Indexed: 01/30/2023]
Affiliation(s)
- Van Anh Ta
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1160, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France
| | - Maxime Battistella
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Pathology Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France
| | - Lin Pierre Zhao
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1160, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France
| | - Gabor Dobos
- Department of Dermatology, Charité Hospital, Berlin, Germany
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Isabelle Madelaine
- Pharmacy, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jean-Christophe Bories
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France
| | - Olivier Tournilhac
- Department of Hematology, Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, France
| | - Jacques Rouanet
- Department of Dermatology, Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, France
| | - Richard Veyrat-Masson
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) Clermont-Ferrand, Clermont-Ferrand, France
| | - Jean-David Bouaziz
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France; Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anne Marie-Cardine
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France
| | - Martine Bagot
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France; Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Armand Bensussan
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France
| | - Hélène Moins-Teisserenc
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1160, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Hematology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Adèle De Masson
- Université Paris Cité, Institut de Recherche Saint-Louis, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U976 HIPI, Institut de Recherche Saint-Louis, Paris, France; Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
| |
Collapse
|
30
|
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet 2023; 401:1941-1950. [PMID: 37105210 DOI: 10.1016/s0140-6736(23)00329-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 01/26/2023] [Accepted: 02/10/2023] [Indexed: 04/29/2023]
Abstract
BACKGROUND Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs. METHODS In this prospective, multicentre, matched controlled trial, conducted at 30 hospitals, participants with advanced CTCLs were allocated treatment: if they had an available compatible related donor they were assigned to allogeneic HSCT, or if not they were allocated to non-allogeneic HSCT therapy. Key inclusion criteria were participants aged 18-70 years, with advanced stage mycosis fungoides or Sézary syndrome, and at least one poor prognostic criteria. Participants were excluded if they were not in complete or partial remission of the disease. Propensity score 1:1 matching with replacement (ie, that each participant treated with HSCT was matched to the participant with the closest propensity score treated with non-HSCT therapy, even if they had already been matched) was used to handle confounding factors, with the balance of covariate distribution between HSCT and non-HSCT groups assessed using standardised mean differences. The primary endpoint was progression-free survival in the matched intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02520908), and is currently active but not recruiting. FINDINGS From June 1, 2016, to March 3, 2022, total of 99 participants were enrolled at 17 centres in France. Participants with a sibling or matched unrelated donor were assigned to allogeneic HSCT (HSCT group, n=55 [56%]) and participants without a donor were assigned to non-allogeneic HSCT treatment (non-HSCT group, n=44 [44%]). The median follow-up among survivors was 12·6 months (IQR 11·0-35·2). In the HSCT group, 51 participants (93%) were 1:1 matched to participants from the non-HSCT group. In the intention-to-treat analysis, median progression-free survival was significantly longer in the HSCT group (9·0 months [95% CI 6·6-30·5]) than in the non-HSCT group (3·0 months [2·0-6·3]), with a hazard ratio of 0·38 (95% CI 0·21-0·69; p<0·0001). In the per-protocol population, 40 participants (78%) in the HSCT group had 101 serious events and 29 participants (67%) in the non-HSCT group had 70 serious adverse events. The most common serious adverse event other than graft-versus-host disease in both groups was infections, occurring in 30 participants (59%) in the HSCT group and in 19 participants (44%) in the non-HSCT group. INTERPRETATION Allogeneic HSCT was associated with significantly longer progression-free survival in participants with advanced-stage CTCLs. These results indicate that allogeneic HSCT treatment should be made available to individuals with high-risk, advanced-stage mycosis fungoides or Sézary syndrome who achieve pre-transplant disease remission. FUNDING French Ministry of Health, National Cancer Institute, Programme Hospitalier de Recherche Clinique en Cancérologie.
Collapse
Affiliation(s)
- Adèle de Masson
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.
| | - Marie Beylot-Barry
- Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Institut National de la Santé et de la Recherche Médicale U1312, Bordeaux Institute of Oncology, Team 5, University of Bordeaux, Bordeaux, France
| | - Caroline Ram-Wolff
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jean-Baptiste Mear
- Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Stéphane Dalle
- Department of Dermatology, Hôpital Lyon-Sud, Lyon, France
| | - Michel d'Incan
- Department of Dermatology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, University Paris-Est Créteil, Créteil, France
| | - Corentin Orvain
- Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France; Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, Angers, France; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1307, Centre National de la Recherche Scientifique Unité Mixte de Recherche 6075, Nantes Université, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, Université d'Angers, Angers, France
| | - Julie Abraham
- Department of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France
| | - Olivier Dereure
- Department of Dermatology and Institut National de la Santé et de la Recherche Médicale U1058 Pathogenesis and Control of Chronic and Emergent Infections, University of Montpellier, Montpellier, France
| | - Amandine Charbonnier
- Department of Hematology, Centre Hospitalier Universitaire d'Amiens, Amiens, France
| | - Jérôme Cornillon
- Department of Clinical Hematology and Cellular Therapy, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France
| | - Christine Longvert
- Department of Dermatology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - Stéphane Barete
- Department of Dermatology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Serge Boulinguez
- Department of Dermatology, Centre Hospitalier Universitaire Toulouse, Toulouse, France
| | - Ewa Wierzbicka-Hainaut
- Department of Dermatology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - François Aubin
- Department of Dermatology, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Marie-Thérèse Rubio
- Department of Hematology, Hôpital Brabois, Centre Hospitalier Régional Universitaire Nancy, Nancy, France; Centre National de la Recherche Scientifique Unité Mixte de Recherche 7365, Ingéniérie Moléculaire et Physiopathologie Articulaire, Biopole, University of Lorraine, Nancy, France
| | - Marc Bernard
- Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Aline Schmidt-Tanguy
- Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - Roch Houot
- Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France; Institut National de la Santé et de la Recherche Médicale U1236, Rennes, France
| | - Anne Pham-Ledard
- Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Institut National de la Santé et de la Recherche Médicale U1312, Bordeaux Institute of Oncology, Team 5, University of Bordeaux, Bordeaux, France
| | - David Michonneau
- Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Pauline Brice
- Department of Hemato-Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | - Jean-David Bouaziz
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Florent Grange
- Department of Dermatology, Centre Hospitalier de Valence, Valence, France
| | - Hélène Moins-Teisserenc
- Hematology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France
| | - Katayoun Jondeau
- Department of Hematology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | - Laurence Michel
- Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Samia Mourah
- Department of Tumor Genomics and Pharmacology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Maxime Battistella
- Pathology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Etienne Daguindau
- Department of Hematology, Centre Hospitalier Universitaire de Besançon, Besançon, France
| | - Michael Loschi
- Department of Hematology, Hôpital L'Archet, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Alexandra Picard
- Department of Dermatology, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Nathalie Franck
- Department of Dermatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Natacha Maillard
- Department of Hematology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Anne Huynh
- Department of Hematology, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
| | - Stéphanie Nguyen
- Department of Hematology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Ambroise Marçais
- Department of Hematology, Centre Hospitalier Universitaire Necker, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Guillaume Chaby
- Department of Dermatology, Centre Hospitalier Universitaire d'Amiens, Amiens, France
| | - Patrice Ceballos
- Department of Hematology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Yannick Le Corre
- Department of Dermatology, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - Sébastien Maury
- Department of Hematology, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - Jacques-Olivier Bay
- Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - Henri Adamski
- Department of Dermatology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - Emmanuel Bachy
- Department of Hematology, Centre Hospitalier Universitaire de Lyon, Lyon, France
| | - Edouard Forcade
- Department of Clinical Hematology and Cellular Therapy, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France
| | - Gérard Socié
- Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France
| | - Sylvie Chevret
- Department of Biostatistics, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France; Institut National de la Santé et de la Recherche Médicale U1153, Paris, France
| | - Régis Peffault de Latour
- Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France.
| |
Collapse
|
31
|
Marcuzzi D, Toigo V, Boldrin M, Chitarin G, Dal Bello S, Grando L, Luchetta A, Pasqualotto R, Pavei M, Serianni G, Zanotto L, Agnello R, Agostinetti P, Agostini M, Aprile D, Barbisan M, Battistella M, Berton G, Bigi M, Brombin M, Candela V, Candeloro V, Canton A, Casagrande R, Cavallini C, Cavazzana R, Cordaro L, Cruz N, Dalla Palma M, Dan M, De Lorenzi A, Delogu R, De Muri M, De Nardi M, Denizeau S, Fadone M, Fellin F, Ferro A, Gaio E, Gasparrini C, Gnesotto F, Jain P, La Rosa A, Lopez-Bruna D, Lorenzini R, Maistrello A, Manduchi G, Manfrin S, Marconato N, Mario I, Martini G, Milazzo R, Patton T, Peruzzo S, Pilan N, Pimazzoni A, Poggi C, Pomaro N, Pouradier-Duteil B, Recchia M, Rigoni-Garola A, Rizzetto D, Rizzolo A, Santoro F, Sartori E, Segalini B, Shepherd A, Siragusa M, Sonato P, Sottocornola A, Spada E, Spagnolo S, Spolaore M, Taliercio C, Tinti P, Tomsič P, Trevisan L, Ugoletti M, Valente M, Valisa M, Veronese F, Vignando M, Zaccaria P, Zagorski R, Zaniol B, Zaupa M, Zuin M, Cavenago M, Boilson D, Rotti C, Decamps H, Geli F, Sharma A, Veltri P, Zacks J, Simon M, Paolucci F, Garbuglia A, Gutierrez D, Masiello A, Mico G, Labate C, Readman P, Bragulat E, Bailly-Maitre L, Gomez G, Kouzmenko G, Albajar F, Kashiwagi M, Tobari H, Kojima A, Murayama M, Hatakeyama S, Oshita E, Maejima T, Shibata N, Yamashita Y, Watanabe K, Singh N, Singh M, Dhola H, Fantz U, Heinemann B, Wimmer C, Wünderlich D, Tsumori K, Croci G, Gorini G, Muraro A, Rebai M, Tardocchi M, Giacomelli L, Rigamonti D, Taccogna F, Bruno D, Rutigliano M, Longo S, Deambrosis S, Miorin E, Montagner F, Tonti A, Panin F. Lessons learned after three years of SPIDER operation and the first MITICA integrated tests. Fusion Engineering and Design 2023. [DOI: 10.1016/j.fusengdes.2023.113590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
|
32
|
Viguier M, Pérals C, Poirier B, Battistella M, Aubin F, Bachelez H, Prétet JL, Gheit T, Tommasino M, Touzé A, Gougeon ML, Fazilleau N. Human papilloma virus-16-specific CD8+ T-cell expansions characterize different clinical forms of lichen planus and not lichen sclerosus et atrophicus. Exp Dermatol 2023; 32:859-868. [PMID: 36922453 DOI: 10.1111/exd.14788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Revised: 02/22/2023] [Accepted: 02/25/2023] [Indexed: 03/18/2023]
Abstract
Lichen planus (LP) is a cutaneomucosal chronic inflammatory disease characterized by a CD8+ cytotoxic T-lymphocytes (CTL) infiltrate. In erosive oral LP, we found HPV16-specific activated CTL in lesions, supporting a pathogenic contribution of HPV16. Here, we investigated whether a similar scenario occurs in other clinical forms of LP and in lichen sclerosus et atrophicus (LSA), another chronic disease also affecting the mucosa and/or the skin. Blood CTL from LP and LSA patients expressed significant higher levels of granzyme B, perforin and CD107a proteins than healthy donors. Expansions of TCRVß3+ CTL, with presence of TCR clonotypes identical to those previously detected in erosive oral LP, were found both in blood and mucosal/skin lesions of LP, and not of LSA patients. These expansions were enriched with HPV16-specific CD8+ T-cells as shown by their recognition of the E711-20 immunodominant epitope. In LSA patients, the peripheral repertoire of CTL was oligoclonal for TCRVß6+ CTL. Finally, although patients with LP and LSA have developed antibodies against HPV16 capsid L1, antibodies against HPV16 E6 were only observed in patients with LP. Overall, our data collectively suggest an involvement of HPV16-specific CTL in different clinical forms of LP, not only in erosive oral LP, while a different scenario operates in LSA.
Collapse
Affiliation(s)
- Manuelle Viguier
- Department of dermatology, Hôpital Robert-Debré, University of Reims Champagne-Ardenne (URCA), EA7509 IRMAIC, Reims, France
| | - Corine Pérals
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), CNRS U5051, INSERM U1291, University Toulouse III, Toulouse, France
| | | | - Maxime Battistella
- Sorbonne Paris Cité, Service d'Anatomo-Pathologie, Hôpital Saint-Louis, Paris, France
| | - François Aubin
- Service de Dermatologie, Centre Hospitalo-Universitaire (CHU) de Besançon, Université de Franche Comté, Besançon, France
| | - Hervé Bachelez
- Laboratory of Genetics of Skin Diseases, Imagine Institute for Human Genetic Diseases, INSERM U1163, Université de Paris, Paris, France
- Department of Dermatology, APHP Hôpital Saint-Louis, Paris, France
| | - Jean-Luc Prétet
- Centre National de Référence Papillomavirus, Laboratoire de Biologie Cellulaire et Moléculaire, CHU de Besançon, Université Bourgogne Franche Comté, Besançon, France
| | | | - Massimo Tommasino
- IARC, Lyon, France
- IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | | | | | - Nicolas Fazilleau
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), CNRS U5051, INSERM U1291, University Toulouse III, Toulouse, France
| |
Collapse
|
33
|
Masson AD, Ram-Wolff C, Bouaziz JD, Cayuela JM, Lorillon G, Frumholtz L, Cassius C, Petit A, Léonard-Louis S, Battistella M, Vignon-Pennamen MD, Rivet J, Meignin V, Duverger L, Jachiet M, Bagot M, Lazaridou I. Dermatomyositis versus mycosis fungoides: Challenges in the diagnosis of erythroderma with associated myositis. Ann Dermatol Venereol 2023; 150:129-133. [PMID: 36682974 DOI: 10.1016/j.annder.2021.04.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Revised: 03/21/2021] [Accepted: 04/12/2021] [Indexed: 01/22/2023]
Affiliation(s)
- A de Masson
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France; Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France
| | - C Ram-Wolff
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - J D Bouaziz
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France; Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France
| | - J M Cayuela
- Laboratory of Hematology, University Hospital Saint-Louis AP-HP and EA3518 Université de Paris, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - G Lorillon
- Department of Pulmonology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - L Frumholtz
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - C Cassius
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France; Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France
| | - A Petit
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - S Léonard-Louis
- Department of Neuropathology, AP-HP, Pitié Salpêtrière Hospital, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - M Battistella
- Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France; Department of Pathology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - M D Vignon-Pennamen
- Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France; Department of Pathology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - J Rivet
- Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France; Department of Pathology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - V Meignin
- Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France; Department of Pathology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - L Duverger
- Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France; Department of Pathology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - M Jachiet
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - M Bagot
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France; Université de Paris, INSERM U976, 1 Avenue Claude Vellefaux, 75010 Paris, France.
| | - I Lazaridou
- Department of Dermatology, AP-HP, Saint-Louis Hospital, 1, avenue Claude Vellefaux, 75010 Paris, France
| |
Collapse
|
34
|
Kervarrec T, Pissaloux D, Paindavoine S, Tirode F, Osio A, Mourah S, Jouenne F, Sohier P, Calonje E, Pekar A, Luna EVE, Goto K, Delalande F, Frouin E, Macagno N, Drouot F, Faisan M, Cribier B, Battistella M, de la Fouchardière A. Recurrent PAK2 rearrangements in poroma with folliculo-sebaceous differentiation. Histopathology 2023. [PMID: 37199682 DOI: 10.1111/his.14940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 04/18/2023] [Accepted: 05/01/2023] [Indexed: 05/19/2023]
Abstract
AIMS Poroma is a benign adnexal neoplasm with differentiation towards the upper portion of the sweat gland apparatus. In 2019, Sekine et al. demonstrated recurrent YAP1::MAML2 and YAP1::NUTM1 fusion in poroma and porocarcinoma. Follicular, sebaceous and/or apocrine differentiation has been reported in rare cases of poroma and whether these tumours constitute a variant of poroma or represent a distinctive tumour is a matter to debate. Herein we describe the clinical, immunophenotypic, and molecular features of 13 cases of poroma with folliculo-sebaceous differentiation. METHODS AND RESULTS Most of the tumours were located on the head and neck region (n = 7), and on the thigh (n = 3). All presented were adults with a slight male predilection. The median tumour size was 10 mm (range: 4-25). Microscopically, lesions displayed features of poroma with nodules of monotonous basophilic cells associated with a second population of larger eosinophilic cells. In all cases, ducts and scattered sebocytes were identified. Infundibular cysts were present in 10 cases. In two cases high mitotic activity was noted, and in three cases cytologic atypia and areas of necrosis were identified. Whole transcriptome RNA sequencing demonstrated in-frame fusion transcripts involving RNF13::PAK2 (n = 4), EPHB3::PAK2 (n = 2), DLG1::PAK2 (n = 2), LRIG1::PAK2 (n = 1), ATP1B3::PAK2 (n = 1), TM9SF4::PAK2 (n = 1), and CTNNA1::PAK2 (n = 1). Moreover, fluorescence in situ hybridisation (FISH) analysis revealed PAK2 rearrangement in an additional case. No YAP1::MAML2 or YAP1::NUTM1 fusion was detected. CONCLUSION Recurrent fusions involving the PAK2 gene in all analysed poroma with folliculo-sebaceous differentiation in this study confirms that this neoplasm represents a separate tumour entity distinct from YAP1::MAML2 or YAP1::NUTM1 rearranged poromas.
Collapse
Affiliation(s)
- Thibault Kervarrec
- Department of Pathology, Centre Hospitalier Universitaire de Tours, Université de Tours, Tours, France
- "Biologie des infections à polyomavirus" Team, UMR INRA ISP 1282, Université de Tours, Tours, France
- CARADERM Network, Lille, France
| | - Daniel Pissaloux
- Department of Biopathology, Center Léon Bérard, Lyon, France
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | | | - Franck Tirode
- Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Amélie Osio
- Department of Pathology, APHP Hôpital Saint Louis, Université Paris 7, Paris, France
| | - Samia Mourah
- Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital, Paris University AP-HP, Paris, France
| | - Fanélie Jouenne
- Department of Pharmacology and Solid Tumor Genomics, Saint Louis Hospital, Paris University AP-HP, Paris, France
| | - Pierre Sohier
- CARADERM Network, Lille, France
- Faculté de Médecine, Université Paris Cité, Paris, France
- Department of Pathology, Hôpital Cochin, AP-HP.Centre-Université Paris Cité, Paris, France
| | - Eduardo Calonje
- Department of Dermatopathology, St John's Institute of Dermatology, St Thomas's Hospital, London, UK
| | - Agnes Pekar
- Department of Dermatopathology, St John's Institute of Dermatology, St Thomas's Hospital, London, UK
| | - Evelyn Vanesa Erazo Luna
- Department of Dermatopathology, St John's Institute of Dermatology, St Thomas's Hospital, London, UK
| | - Keisuke Goto
- Department of Pathology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan
- Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Sunto, Japan
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan
- Department of Dermatology, Hyogo Cancer Center, Akashi, Japan
| | - Flore Delalande
- Department of Pathology, Hospital Center of Orléans, Orléans, France
| | - Eric Frouin
- CARADERM Network, Lille, France
- Department of Pathology, University hospital of Poitiers, Poitiers, France
| | - Nicolas Macagno
- CARADERM Network, Lille, France
- Department of Pathology, Timone University Hospital, Marseille, France
| | - Françoise Drouot
- CARADERM Network, Lille, France
- Department of Pathology, Cypath, Dijon, France
| | - Monique Faisan
- CARADERM Network, Lille, France
- Department of Pathology, Cypath, Lyon, France
| | - Bernard Cribier
- CARADERM Network, Lille, France
- Dermatology Clinic, Hôpitaux Universitaires & Université de Strasbourg, Hôpital Civil, Strasbourg, France
| | - Maxime Battistella
- CARADERM Network, Lille, France
- Department of Pathology, APHP Hôpital Saint Louis, Université Paris 7, Paris, France
- Department of Pathology, APHP Hôpital Saint Louis, INSERM U976, Université Paris Cité 7, Paris, France
| | | |
Collapse
|
35
|
Luchetta A, Dal Bello S, Battistella M, Grando L, Moressa M, Paolucci F, Labate C, Agnoletto G. As built design, commissioning and integration of the SPIDER and NBTF central safety systems. Fusion Engineering and Design 2023. [DOI: 10.1016/j.fusengdes.2023.113536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
36
|
Toulemonde E, Chevret S, Battistella M, Neidhardt EM, Nardin C, Le Du F, Meyer N, Véron M, Gambotti L, Lamrani-Ghaouti A, Jamme P, Chaffaut C, De Pontville M, Saada-Bouzid E, Beylot-Barry M, Simon C, Jouary T, Marabelle A, Mortier L. Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas. Cancer Immunol Immunother 2023:10.1007/s00262-023-03449-9. [PMID: 37067554 DOI: 10.1007/s00262-023-03449-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2022] [Accepted: 04/06/2023] [Indexed: 04/18/2023]
Abstract
Trichoblastic carcinoma is a rare malignant cutaneous adnexal tumor with a risk of local invasion and distant metastasis. As of today, there is no consensus for the treatment of locally advanced or metastatic trichoblastic carcinoma. "AcSé Nivolumab" is a multi-center Phase II basket clinical trial (NCT03012581) evaluating the safety and efficacy of nivolumab in several cohorts of rare, advanced cancers. Here we report the results of nivolumab in patients with trichoblastic carcinoma. Of the eleven patients enrolled in the study, five patients had been previously treated by sonic hedgehog inhibitors. The primary endpoint 12-week objective response rate was 9.1% (N = 1/11) with 1 partial response. Six patients who progressed under previous lines of treatment showed stable disease at 12 weeks, reflecting a good control of the disease with nivolumab. Furthermore, 54.5% of the patients (N = 6/11) had their disease under control at 6 months. The 1-year overall survival was 80%, and the median progression-free survival was 8.4 months (95%CI, 5.7 to NA). With 2 responders (2 complete responses), the best response rate to nivolumab at any time was 18.2% (95%CI, 2.3-51.8%). No new safety signals were identified, and adverse events observed herein were previously described and well known with nivolumab monotherapy. These results are promising, suggesting that nivolumab might be an option for patients with advanced trichoblastic carcinomas. Further studies on larger cohorts are necessary to confirm these results and define the role of nivolumab in the treatment of trichoblastic carcinomas.
Collapse
Affiliation(s)
- E Toulemonde
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France.
| | - S Chevret
- Department of Biostatistics, Saint Louis Hospital, AP-HP, Paris, France
| | - M Battistella
- Department of Pathology, Saint Louis Hospital, AP-HP, Université Paris Cité, INSERM U976, Paris, France
- CARADERM Network, Lille, France
| | - E M Neidhardt
- Department of Oncology, Centre Léon Berard, Lyon, France
| | - C Nardin
- Department of Dermatology, CHU Besançon and INSERM 1098, Besançon, France
| | - F Le Du
- Department of Oncology, CLCC Eugène Marquis, Rennes, France
| | - N Meyer
- Department of Oncodermatology, IUC and CHU Toulouse, Toulouse, France
| | - M Véron
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France
| | - L Gambotti
- Department of Clinical Research, Institut National Contre Le Cancer (INCa), Paris, France
| | | | - P Jamme
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France
| | - C Chaffaut
- Department of Biostatistics, Saint Louis Hospital, AP-HP, Paris, France
| | - M De Pontville
- Department of Dermatology, CHU Caen, Caen, France
- CARADERM Network, Lille, France
| | - E Saada-Bouzid
- Department of Medical Oncology, Centre Antoine Lacassagne, Côte d'Azur University, Nice, France
| | - M Beylot-Barry
- Department of Dermatology, CHU Bordeaux, INSERM U1312, Bordeaux, France
- CARADERM Network, Lille, France
| | - C Simon
- Département R&D Unicancer, Paris, France
| | - T Jouary
- Department of Dermatology, François Mitterrand Hospital, Pau, France
- CARADERM Network, Lille, France
| | - A Marabelle
- Department of Therapeutic Innovations and Early Clinical Trials, INSERM U1015 & CIC1428, University of Paris Saclay, Gustave Roussy, Villejuif, France
| | - L Mortier
- Department of Dermatology, Claude Huriez Hospital, CARADERM and University of Lille, U1189 Inserm, 59000, Lille, France
- CARADERM Network, Lille, France
| |
Collapse
|
37
|
Quaglino P, Scarisbrick J, Roccuzzo G, Abeldano A, Battistella M, McCormack C, Cowan R, Cozzio A, Cury-Martins J, Enz P, Geskin L, Guenova E, Kim YH, Knobler R, Litvinov IV, Miyagaki T, Molgo M, Nicolay J, Papadavid E, Pinter-Brown L, Pujol Vallverdu R, Querfeld C, Ortiz-Romero P, Stadler R, Vermeer MH, Bagot M, Hodak E. Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey. J Eur Acad Dermatol Venereol 2023; 37:680-688. [PMID: 36606565 DOI: 10.1111/jdv.18852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Accepted: 12/13/2022] [Indexed: 01/07/2023]
Abstract
BACKGROUND Consensus about the definition and classification of 'plaque' in mycosis fungoides is lacking. OBJECTIVES To delineate a comprehensive view on how the 'plaque' entity is defined and managed in clinical practice; to evaluate whether the current positioning of plaques in the TNMB classification is adequate. METHODS A 12-item survey was circulated within a selected panel of 22 experts (pathologists, dermatologists, haematologists and oncologists), members of the EORTC and International Society for Cutaneous Lymphoma. The questionnaire discussed clinical and histopathological definitions of plaques and its relationship with staging and treatment. RESULTS Total consensus and very high agreement rates were reached in 33.3% of questions, as all panellists regularly check for the presence of plaques, agree to evaluate the presence of plaques as a potential separate T class, and concur on the important distinction between plaque and patch for the management of early-stage MF. High agreement was reached in 41.7% of questions, since more than 50% of the responders use Olsen's definition of plaque, recommend the distinction between thin/thick plaques, and agree on performing a biopsy on the most infiltrated/indurated lesion. High divergence rates (25%) were reported regarding the possibility of a clinically based distinction between thin and thick plaques and the role of histopathology to plaque definition. CONCLUSIONS The definition of 'plaque' is commonly perceived as a clinical entity and its integration with histopathological features is generally reserved to specific cases. To date, no consensus is achieved as for the exact definition of thin and thick plaques and current positioning of plaques within the TNMB system is considered clinically inadequate. Prospective studies evaluating the role of histopathological parameters and other biomarkers, as well as promising diagnostic tools, such as US/RM imaging and high-throughput blood sequencing, are much needed to fully integrate current clinical definitions with more objective parameters.
Collapse
Affiliation(s)
- Pietro Quaglino
- Dermatologic Clinic, Department of Medical Sciences, University of Torino, Torino, Italy
| | | | - Gabriele Roccuzzo
- Dermatologic Clinic, Department of Medical Sciences, University of Torino, Torino, Italy
| | - Alejandra Abeldano
- Hospital Gral. de Agudos Dr. C. Argerich, Ciudad de Buenos Aires, Buenos Aires, Argentina
| | - Maxime Battistella
- Université Paris Cité, INSERM U976 HIPI, Paris, France.,Department of Pathology, AP-HP Saint-Louis Hospital, Paris, France
| | - Chris McCormack
- Surgical Oncology Department, Peter MacCallum Cancer Centre, Parkvile, Victoria, Australia
| | - Richard Cowan
- Department of Clinical Oncology, The Christie Hospital, Manchester, UK
| | - Antonio Cozzio
- Faculty of Medicine, University of Zurich, Zurich, Switzerland
| | - Jade Cury-Martins
- Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil
| | - Paula Enz
- Hospital Italiano de Buenos Aires, Ciudad de Buenos Aires, Buenos Aires, Argentina
| | - Larisa Geskin
- Columbia University Medical Center, New York, New York, USA
| | | | - Youn H Kim
- Stanford Cancer Institute, Stanford, California, USA
| | - Robert Knobler
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Ivan V Litvinov
- Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada
| | - Tomomitsu Miyagaki
- Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Japan
| | - Montserrat Molgo
- Department of Dermatology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Jan Nicolay
- Department of Dermatology, University Medical Center Mannheim, Mannheim, Germany
| | - Evangelina Papadavid
- 2nd Department of Dermatology and Venereology, ATTIKON University Hospital, Athens, Greece
| | | | | | | | - Pablo Ortiz-Romero
- Hospital 12 de Octubre, Institute I+12, CIBERONC, Medical School, Universidad Complutense, Madrid, Spain
| | - Rudolf Stadler
- University Hospitals of the Ruhr-University of Bochum, Minden, Germany
| | - Maarten H Vermeer
- Department of Dermatology, Leiden University Medical Center, RC Leiden, The Netherlands
| | | | - Emmilia Hodak
- Rabin Medical Center, Beilinson Hospital, Petah Tiqva, Israel
| |
Collapse
|
38
|
Stammler R, Bessis D, Meunier L, Limal N, Guillaud C, Mahévas M, Bagot M, Charvet E, Cassius C, Battistella M, Bouaziz JD, Mahévas T. Jadassohn-Dössekker's atypical tuberous myxedema: report of three cases and review of literature. J Eur Acad Dermatol Venereol 2023. [PMID: 36913246 DOI: 10.1111/jdv.19029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 03/08/2023] [Indexed: 03/14/2023]
Affiliation(s)
- Romain Stammler
- AP-HP, Dermatology Department, Saint Louis Hospital, Paris, France
| | - Didier Bessis
- Dermatology Department, Montpellier University Hospital Center, Montpellier, France
| | - Laurent Meunier
- Dermatology Department, Montpellier University Hospital Center, Montpellier, France
| | - Nicolas Limal
- AP-HP, Internal Medicine Department, referral center for autoimmune cytopenia, Mondor Hospital, Paris Est Creteil University, Creteil, France
| | - Constance Guillaud
- AP-HP, Post-Emergency Department, Mondor Hospital, Paris Est Creteil University, Creteil, France
| | - Matthieu Mahévas
- AP-HP, Internal Medicine Department, referral center for autoimmune cytopenia, Mondor Hospital, Paris Est Creteil University, Creteil, France
| | - Martine Bagot
- AP-HP, Dermatology Department, Saint Louis Hospital, Paris, France
| | - Estelle Charvet
- AP-HP, Dermatology Department, Saint Louis Hospital, Paris, France
| | - Charles Cassius
- AP-HP, Dermatology Department, Saint Louis Hospital, Paris, France
| | - Maxime Battistella
- AP-HP, Pathology Department, Saint-Louis Hospital, Université Paris Cité, INSERM U976, Paris, France
| | | | - Thibault Mahévas
- AP-HP, Dermatology Department, Saint Louis Hospital, Paris, France
| |
Collapse
|
39
|
Moghadam P, Bellaiche S, Mausoleo A, Cassius C, Zuelgaray E, Mahevas T, Vignon-Pennamen MD, Battistella M, Bagot M, Bouaziz JD. Lichen planus associated with eosinophilic fasciitis outside the setting of chronic graft-versus-host disease. Ann Dermatol Venereol 2023; 150:71-72. [PMID: 36428118 DOI: 10.1016/j.annder.2022.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 05/01/2022] [Accepted: 09/28/2022] [Indexed: 11/23/2022]
Affiliation(s)
- P Moghadam
- Dermatology Department, Saint-Louis Hospital, Paris, France.
| | - S Bellaiche
- Dermatology Department, Saint-Louis Hospital, Paris, France
| | - A Mausoleo
- Dermatology Department, Saint-Louis Hospital, Paris, France
| | - C Cassius
- Dermatology Department, Saint-Louis Hospital, Paris, France; Université de Paris, INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, 75010 Paris, France
| | - E Zuelgaray
- Dermatology Department, Saint-Louis Hospital, Paris, France; Université de Paris, INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, 75010 Paris, France
| | - T Mahevas
- Dermatology Department, Saint-Louis Hospital, Paris, France; Université de Paris, INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, 75010 Paris, France
| | | | - M Battistella
- Pathology Department, Saint-Louis Hospital, Paris, France
| | - M Bagot
- Dermatology Department, Saint-Louis Hospital, Paris, France; Université de Paris, INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, 75010 Paris, France
| | - J-D Bouaziz
- Dermatology Department, Saint-Louis Hospital, Paris, France; Université de Paris, INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, 75010 Paris, France
| |
Collapse
|
40
|
De Clippele D, Frumholtz L, Vignon-Pennamen MD, Molina T, Moatti H, Battistella M, Ochmann M, Ram-Wolff C, Petit A, Bagot M, De Masson A. Periorbital erythema and oedema revealing angioimmunoblastic T cell lymphoma. Eur J Dermatol 2023; 33:58-59. [PMID: 37178041 DOI: 10.1684/ejd.2023.4426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Affiliation(s)
| | - Laure Frumholtz
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | | | - Thierry Molina
- Université Paris Cité, Paris, France, Department of Pathology, APHP, Necker, Paris, France
| | - Hannah Moatti
- Department of Hematology, APHP, Saint-Louis Hospital, Paris, France
| | - Maxime Battistella
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France, Université Paris Cité, Paris, France
| | - Marlène Ochmann
- Department of Hematology, Centre Hospitalier Régional d'Orléans, Orléans, France
| | | | - Antoine Petit
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Martine Bagot
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France, Department of Pathology, APHP, Saint-Louis Hospital, Paris, France
| | - Adèle De Masson
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France, Université Paris Cité, Paris, France
| |
Collapse
|
41
|
Kervarrec T, Frouin E, Collin C, Tallet A, Tallegas M, Pissaloux D, Tirode F, Guyétant S, Samimi M, Gaboriaud P, Touzé A, Schrama D, Houben R, Tabareau-Delalande F, Neuhart A, de la Fouchardière A, Osio A, Cavelier-Balloy B, Laurent-Roussel S, Sohier P, Cyprien T, Balme B, Belzung F, Jullie ML, Cribier B, Battistella M, Macagno N. Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1-deficient skin carcinoma. Histopathology 2023; 82:885-898. [PMID: 36720791 DOI: 10.1111/his.14874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 12/22/2022] [Accepted: 01/15/2023] [Indexed: 02/02/2023]
Abstract
AIMS Recently, YAP1 fusion genes have been demonstrated in eccrine poroma and porocarcinoma, and the diagnostic use of YAP1 immunohistochemistry has been highlighted in this setting. In other organs, loss of YAP1 expression can reflect YAP1 rearrangement or transcriptional repression, notably through RB1 inactivation. In this context, our objective was to re-evaluate the performance of YAP1 immunohistochemistry for the diagnosis of poroma and porocarcinoma. METHODS AND RESULTS The expression of the C-terminal part of the YAP1 protein was evaluated by immunohistochemistry in 543 cutaneous epithelial tumours, including 27 poromas, 14 porocarcinomas and 502 other cutaneous tumours. Tumours that showed a lack of expression of YAP1 were further investigated for Rb by immunohistochemistry and for fusion transcripts by real-time PCR (YAP1::MAML2 and YAP1::NUTM1). The absence of YAP1 expression was observed in 24 cases of poroma (89%), 10 porocarcinoma (72%), 162 Merkel cell carcinoma (98%), 14 squamous cell carcinoma (SCC) (15%), one trichoblastoma and one sebaceoma. Fusions of YAP1 were detected in only 16 cases of poroma (n = 66%), 10 porocarcinoma (71%) all lacking YAP1 expression, and in one sebaceoma. The loss of Rb expression was detected in all cases except one of YAP1-deficient SCC (n = 14), such tumours showing significant morphological overlap with porocarcinoma. In-vitro experiments in HaCat cells showed that RB1 knockdown resulted in repression of YAP1 protein expression. CONCLUSION In addition to gene fusion, we report that transcriptional repression of YAP1 can be observed in skin tumours with RB1 inactivation, including MCC and a subset of SCC.
Collapse
Affiliation(s)
- Thibault Kervarrec
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, University Hospital of Tours, Tours, France.,'Biologie des Infections à Polyomavirus' Team, UMR1282 INRAE, University of Tours, Tours, France
| | - Eric Frouin
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, University Hospital of Poitiers, University of Poitiers, LITEC, Poitiers, France
| | - Christine Collin
- Platform of Solid Tumor Molecular Genetics, University Hospital Center of Tours, Tours, France
| | - Anne Tallet
- Platform of Solid Tumor Molecular Genetics, University Hospital Center of Tours, Tours, France
| | - Matthias Tallegas
- Platform of Solid Tumor Molecular Genetics, University Hospital Center of Tours, Tours, France
| | - Daniel Pissaloux
- Department of Biopathology, Center Léon Bérard, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Franck Tirode
- Department of Biopathology, Center Léon Bérard, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Serge Guyétant
- Department of Pathology, University Hospital of Tours, Tours, France.,'Biologie des Infections à Polyomavirus' Team, UMR1282 INRAE, University of Tours, Tours, France.,Department of Pathology, University Hospital of Poitiers, University of Poitiers, LITEC, Poitiers, France
| | - Mahtab Samimi
- Department of Dermatology, University Hospital Center of Tours, Tours, France
| | - Pauline Gaboriaud
- 'Biologie des Infections à Polyomavirus' Team, UMR1282 INRAE, University of Tours, Tours, France
| | - Antoine Touzé
- 'Biologie des Infections à Polyomavirus' Team, UMR1282 INRAE, University of Tours, Tours, France
| | - David Schrama
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
| | - Roland Houben
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
| | | | - Anne Neuhart
- Department of Biopathology, Center Léon Bérard, Lyon, France
| | - Arnaud de la Fouchardière
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Biopathology, Center Léon Bérard, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Equipe Labellisée Ligue contre le Cancer, Lyon, France
| | - Amélie Osio
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, Hospital Saint-Louis, AP-HP, Université Paris Cité, INSERM U976, Paris, France.,Centre National de Dermatopathologie, Paris-la Roquette, Ivry, France
| | | | - Sara Laurent-Roussel
- Centre National de Dermatopathologie, Paris-la Roquette, Ivry, France.,Cabinet Mathurin Moreau, Paris, France
| | - Pierre Sohier
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, Hôpital Cochin, AP-HP, AP-HP.Centre - Université Paris Cité, Paris, France.,Faculté de Médecine, University Paris Cité, Paris, France
| | - Tilmant Cyprien
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, Groupement des Hopitaux de l'institut catholique de Lille, Lille, France
| | - Brigitte Balme
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, University Hospital of Lyon Sud, Lyon, France
| | - Fanny Belzung
- Department of Pathology, University Hospital of Bordeaux, Bordeaux, France
| | - Marie-Laure Jullie
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, University Hospital of Bordeaux, Bordeaux, France
| | - Bernard Cribier
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Clinique Dermatologique, Hôpitaux Universitaires and Université de Strasbourg, Hôpital Civil, Strasbourg, France
| | - Maxime Battistella
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, Hospital Saint-Louis, AP-HP, Université Paris Cité, INSERM U976, Paris, France
| | - Nicolas Macagno
- CARADERM, French Network of Rare Cutaneous Cancer, Lille, France.,Department of Pathology, APHM, Timone University Hospital, Marseille, France.,Aix-Marseille University, INSERM U1251, MMG, Marseille, France
| |
Collapse
|
42
|
Oulès B, Deschamps L, Sohier P, Tihy M, Chassac A, Couvelard A, Frouin E, Battistella M. Diagnostic Accuracy of GATA6 Immunostaining in Sebaceous Tumors of the Skin. Mod Pathol 2023; 36:100101. [PMID: 36788082 DOI: 10.1016/j.modpat.2023.100101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 01/04/2023] [Accepted: 01/06/2023] [Indexed: 01/19/2023]
Abstract
The accurate diagnosis of skin adnexal neoplasms is sometimes challenging but is necessary because medical management and follow-up may differ between tumors. GATA6 transcription factor has been identified as a new marker of the upper folliculosebaceous compartment (lower infundibulum, junctional zone and isthmus, and upper sebaceous gland) in the human skin. We aimed to determine the diagnostic accuracy of GATA6 immunostaining to diagnose sebaceous tumors compared with that to diagnose other adnexal and nonadnexal cutaneous neoplasms. We conducted a retrospective, evaluator-nonblinded study comparing the reference standard (diagnosis by an expert dermatopathologist) with GATA6 immunostaining to identify sebaceous tumors in a cohort containing 234 different tumors. The GATA6 expression score was significatively higher in sebaceous than that in nonsebaceous tumors. In addition, tumors originating from the upper hair follicle showed positive results for GATA6 staining; however, they showed lower GATA6 expression scores. Detection of sebaceous tumors using GATA6 positivity had a sensitivity of 95.7% (95% confidence interval [95% CI], 85.8-99.2), specificity of 80.8% (95% CI, 74.5-85.8), positive predictive value of 55.6% (95% CI, 44.7-65.9), and negative predictive value of 98.7% (95% CI, 95.4-99.8). GATA6 showed similar sensitivity to adipophilin, the reference marker; however, the specificity of GATA6 was higher, as observed in a cohort of 106 tumors enriched in squamous cell carcinomas with clear-cell histology. In addition, GATA6 positivity was assessed in 39 sebaceous carcinomas and compared with epithelial membrane antigen (EMA), CK7, and androgen receptor (AR) staining results. Although CK7 staining displayed lower diagnostic performances, GATA6 staining showed comparable results as EMA and AR. Finally, we found GATA6 expression in skin metastases of gastrointestinal origin, whereas GATA6 was absent in metastases originating from breast or lung cancers. Overall, our work identified GATA6 immunostaining as a new diagnostic tool for sebaceous tumors.
Collapse
Affiliation(s)
- Bénédicte Oulès
- Cutaneous Biology Lab, Institut Cochin, INSERM U1016, UMR 8104, Paris, France; Department of Dermatology, Hôpital Cochin, AP-HP Centre-Université Paris Cité, Paris, France; Faculté de Médecine Paris Centre Santé, University Paris Cité, Paris, France
| | - Lydia Deschamps
- Department of Pathology, Hôpital Bichat, AP-HP Nord-Université Paris Cité, Paris, France; CARADERM, French Network of Rare Cutaneous Cancers, Lille, France
| | - Pierre Sohier
- Cutaneous Biology Lab, Institut Cochin, INSERM U1016, UMR 8104, Paris, France; Faculté de Médecine Paris Centre Santé, University Paris Cité, Paris, France; CARADERM, French Network of Rare Cutaneous Cancers, Lille, France; Department of Pathology, Hôpital Cochin, AP-HP Centre-Université Paris Cité, Paris, France
| | - Matthieu Tihy
- Department of Pathology, Hôpitaux Universitaires Genève, Geneva, Switzerland
| | - Anaïs Chassac
- Department of Pathology, Hôpital Bichat, AP-HP Nord-Université Paris Cité, Paris, France
| | - Anne Couvelard
- Faculté de Médecine Paris Centre Santé, University Paris Cité, Paris, France; Department of Pathology, Hôpital Bichat, AP-HP Nord-Université Paris Cité, Paris, France; Centre de Recherche sur l'Inflammation, INSERM UMR1149, Faculté de Médecine Bichat, Paris, France
| | - Eric Frouin
- CARADERM, French Network of Rare Cutaneous Cancers, Lille, France; Department of Pathology, Centre Hospitalier Universitaire Poitiers, Poitiers, France
| | - Maxime Battistella
- Faculté de Médecine Paris Centre Santé, University Paris Cité, Paris, France; CARADERM, French Network of Rare Cutaneous Cancers, Lille, France; Department of Pathology, Hôpital Saint Louis, AP-HP Nord-Université Paris Cité, Paris, France; Onco-dermatology and Therapies Lab, Human Immunology, Pathophysiology, Immunotherapy, INSERM U976, Paris, France.
| |
Collapse
|
43
|
Lazaridou I, Calvani J, Annabi E, Moins-Teisserenc H, Ta VA, Rivet J, Ram-Wolff C, Dumont M, Mahevas T, Vignon-Pennamen MD, Mourah S, Bouaziz JD, Louveau B, Bagot M, Battistella M, de Masson A. Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol 2023; 37:e715-e717. [PMID: 36645855 DOI: 10.1111/jdv.18868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Accepted: 01/09/2023] [Indexed: 01/18/2023]
Affiliation(s)
- Ingrid Lazaridou
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Julien Calvani
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France
| | - Elissa Annabi
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Hélène Moins-Teisserenc
- Université Paris Cité, Paris, France.,Hematology Laboratory, APHP, Saint-Louis Hospital, Paris, France.,INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
| | - Van Anh Ta
- INSERM U1160, Institut de Recherche Saint-Louis, Paris, France
| | - Jacqueline Rivet
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France
| | | | - Maëlle Dumont
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | - Thibault Mahevas
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France
| | | | - Samia Mourah
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France.,Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | - Jean-David Bouaziz
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France
| | - Baptiste Louveau
- INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France.,Pharmacology and Solid Tumor Genomics, APHP, Saint-Louis Hospital, Paris, France
| | - Martine Bagot
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France
| | - Maxime Battistella
- Department of Pathology, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France
| | - Adèle de Masson
- Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.,INSERM U976, Institut de Recherche Saint-Louis, Paris, France.,Université Paris Cité, Paris, France
| |
Collapse
|
44
|
Grolleau C, Calugareanu A, Demouche S, Nosbaum A, Staumont-Sallé D, Aubert H, Cassius C, Jachiet M, Saussine A, Bagot M, Bachelez H, Battistella M, Hotz C, Du Thanh A, Crépy MN, Bergerat D, Merandet M, Onifarasoaniaina R, Alberdi A, How-Kit A, Bouaziz JD, Le-Buanec H. IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis. J Invest Dermatol 2023; 143:711-721.e7. [PMID: 36610660 DOI: 10.1016/j.jid.2022.10.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Revised: 10/14/2022] [Accepted: 10/18/2022] [Indexed: 01/07/2023]
Abstract
Dupilumab is a therapeutic antibody targeting IL-4 and IL-13 receptor subunit alpha used for the treatment of patients with atopic dermatitis (AD). Cases of psoriasis-like reactions induced under dupilumab treatment (dupilumab-induced psoriatic eruption [DI-Pso]) for AD were recently reported. To understand the pathogenesis of DI-Pso, we performed gene expression profiling studies on skin biopsies of DI-Pso (n = 7) compared with those of plaque psoriasis, AD, and healthy controls (n = 4 each). Differential gene expression was performed using enrichment and Gene Ontology analysis. Gene expression was validated by qPCR, and protein levels were assessed by immunohistochemistry. Transcriptomic and protein analysis of DI-Pso compared with that of healthy controls, plaque psoriasis, and AD skins revealed activation of T helper 17/IL-23 pathways associated with a significant expression of IL-36, surrogate marker of pustular psoriasis. By contrast, T helper 2 representative genes' expression was strongly decreased in DI-Pso across comparison. Matching analysis with public data of pustular psoriasis skin corroborated that DI-Pso and pustular psoriasis upstream regulators overlap, greater than the overlap with plaque psoriasis. Furthermore, DI-Pso showed strongly decreased expression of many barrier skin genes compared with healthy controls, plaque psoriasis, and AD. Our data indicate that the pathogenesis of DI-Pso relied on a shift of skin immune responses from a T helper 2 to an IL-36 and T helper 17 polarization and on intensified skin barrier alterations.
Collapse
Affiliation(s)
- Chloé Grolleau
- Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| | - Andreea Calugareanu
- Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France; Dermatology Department, University Hospital of Lyon, Lyon, France
| | - Sarah Demouche
- Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| | - Audrey Nosbaum
- Dermatology Department, University Hospital of Lyon, Lyon, France
| | - Delphine Staumont-Sallé
- Dermatology Department, U1286 Inserm Lille Inflammation Translational Research Institute, University of Lille, Lille, France
| | - Hélène Aubert
- Dermatology Department, University Hospital of Nantes, Nantes, France
| | - Charles Cassius
- Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| | - Marie Jachiet
- Dermatology Department, Saint Louis Hospital, Paris, France
| | - Anne Saussine
- Dermatology Department, Saint Louis Hospital, Paris, France
| | - Martine Bagot
- Dermatology Department, Saint Louis Hospital, Paris, France
| | - Hervé Bachelez
- Dermatology Department, Saint Louis Hospital, Paris, France; Laboratory of Genetic of Skin Diseases, INSERM U1163, Imagine Institute, University of Paris, Paris, France
| | | | - Claire Hotz
- Dermatology Department, Henri Mondor Hospital, Créteil, France
| | - Aurélie Du Thanh
- Dermatology Department, University Hospital of Montpellier, Montpellier, France
| | - Marie-Noëlle Crépy
- Dermatology Department, Paris University Hospital of Cochin, Paris, France
| | - David Bergerat
- Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| | - Marine Merandet
- Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| | | | - Antonio Alberdi
- Technological Platerform of Saint- Louis Research Institute (IRSL), Saint-Louis Hospital, University of Paris, Paris, France
| | - Alexandre How-Kit
- Laboratory of Genomics, Foundation Jean Dausset (CEPH), Paris, France
| | - Jean-David Bouaziz
- Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France.
| | - Hélène Le-Buanec
- Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| |
Collapse
|
45
|
Ginguay A, Kramkimel N, Lecolant S, Goldwasser F, Battistella M, Arrondeau J. Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA? Case Rep Oncol 2022; 15:1114-1119. [PMID: 36655184 PMCID: PMC9841795 DOI: 10.1159/000525524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Accepted: 05/17/2022] [Indexed: 12/24/2022] Open
Abstract
Primary cutaneous mucinous carcinoma (PCMC) is a rare malignant skin adnexal tumor. Recurrences are most often localized, and long-term follow-up after complete surgery consists essentially of self-examination of skin. We report one case of metastatic PCMC with elevated levels of serum CEA and CA15.3. Because of the difficulty to differentiate PCMC and metastasis of mucinous breast cancer, the hypothesis of a metastasized breast cancer was ruled out. These tumor markers contributed to the monitoring of the metastatic disease. Since metastatic disease was diagnosed after several years of seeming complete remission, CEA and CA15.3 would likely have allowed the clinicians to detect the relapse earlier. Although the use of tumor biomarkers in PCMC is not rooted in clinical practice and not mentioned in guidelines, we suggest that CEA and CA15.3 could be of particular interest to monitor and detect early metastatic PCMC.
Collapse
Affiliation(s)
- Antonin Ginguay
- Clinical Chemistry Department, Cochin Hospital, Paris Centre University Hospitals, AP-HP, Paris, France,*Antonin Ginguay,
| | - Nora Kramkimel
- Dermatology Department, Cochin Hospital, Paris Centre University Hospitals, AP-HP, Paris, France
| | - Solène Lecolant
- Clinical Chemistry Department, Cochin Hospital, Paris Centre University Hospitals, AP-HP, Paris, France
| | - François Goldwasser
- Medical Oncology Department, Cochin Hospital, Paris Centre University Hospitals, AP-HP, Paris, France
| | - Maxime Battistella
- Pathology Department, Saint-Louis Hospital, Paris Nord University Hospitals, AP-HP, Paris, France
| | - Jennifer Arrondeau
- Medical Oncology Department, Cochin Hospital, Paris Centre University Hospitals, AP-HP, Paris, France
| |
Collapse
|
46
|
Laurent C, Lefèvre G, Kahn JE, Staumont-Salle D, Felten R, Puget M, Moulinet T, Machelart I, Launay D, Charvet E, Bouaziz JD, Jachiet M, Espitia A, Mahr A, Le Clech C, Malphettes M, Morice C, Mourah S, Moins-Teisserenc H, Lifermann F, Soulier-Guérin K, Villate A, Baillou C, Grados A, Robbins A, Abisror N, Bagot M, Boutboul D, Panel K, Vignon-Pennamen MD, Rivet J, Battistella M, Groh M, de Masson A. Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome. Br J Dermatol 2022; 187:1011-1013. [PMID: 35862277 PMCID: PMC10087750 DOI: 10.1111/bjd.21782] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Revised: 07/12/2022] [Accepted: 07/12/2022] [Indexed: 12/24/2022]
Affiliation(s)
- Claire Laurent
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France
| | - Guillaume Lefèvre
- CHU Lille, Institut d'Immunologie, National Reference Centers for Hypereosinophilic syndromes, U1286 - INFINITE - Institute for Translational Research in Inflammation Inserm Univ. Lille, Lille, F-59000, Lille, France
| | - Jean-Emmanuel Kahn
- Department of Internal Medicine, Ambroise-Paré Hospital, Boulogne-Billancourt, France
| | - Delphine Staumont-Salle
- CHU Lille, Univ. Lille, Service de Dermatologie, U1286 Inserm INFINITE Institute for Translational Research in Inflammation, F-59000, Lille
| | - Renaud Felten
- Service de Rhumatologie, Centre de Référence National des Maladies Auto-Immunes Systémiques Rares, CNR RESO, Hôpitaux universitaire de Strasbourg, Strasbourg, France
| | - Marie Puget
- Department of Internal Medicine, CHU de Valence, Valence, France
| | - Thomas Moulinet
- Department of Internal Medicine and Clinical Immunology, CHRU de Nancy, Université de Lorraine, CNRS UMR 7365, IMoPA, Nancy, France
| | - Irène Machelart
- Department of Internal Medicine, CH de Bayonne, Bayonne, France
| | - David Launay
- Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne et Immunologie Clinique, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France
| | | | - Jean David Bouaziz
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Paris, France.,Université Paris Cité, Paris, France
| | - Marie Jachiet
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France
| | - Alexandra Espitia
- Department of Internal Medicine, CHU Nantes Hôtel Dieu, Nantes, France
| | - Alfred Mahr
- Rheumatology Clinic, Kantonsspital St. Gallen, St. Gallen, Switzerland
| | | | - Marion Malphettes
- Department of Clinical Immunology, Saint-Louis Hospital, AP-HP, Paris, France
| | - Cécile Morice
- Department of Dermatology, CHU de Caen, Caen, France
| | - Samia Mourah
- Department of Internal Medicine, CHU Nantes Hôtel Dieu, Nantes, France.,Pharmacogenomics and Oncogenetics, Saint-Louis Hospital, AP-HP, Paris, France
| | - Hélène Moins-Teisserenc
- Université Paris Cité, Paris, France.,Hematology Laboratory and Saint-Louis Hospital, AP-HP, Paris, France
| | | | - Karine Soulier-Guérin
- Department of Internal Medicine and Clinical Immunology, Centre Hospitalier de Vichy, Vichy, France
| | - Alban Villate
- Department of Hematology, CHRU Bretonneau, Tours, France
| | - Chloé Baillou
- Department of Clinical Immunology, CHU Poitiers, Poitiers, France
| | - Aurélie Grados
- Department of Clinical Immunology, CH Niort, Niort, France
| | - Ailsa Robbins
- Department of Internal Medicine, CHU de Reims, Reims, France
| | - Noemie Abisror
- Department of Internal Medicine, CHU Tenon, Paris, France
| | - Martine Bagot
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Paris, France.,Université Paris Cité, Paris, France
| | - David Boutboul
- Department of Clinical Immunology, Saint-Louis Hospital, AP-HP, Paris, France
| | - Kewin Panel
- Department of Internal Medicine, Hôpital Foch, Suresnes, France
| | | | - Jacqueline Rivet
- Department of Pathology, Saint-Louis Hospital, AP-HP, Paris, France
| | - Maxime Battistella
- INSERM U976, Paris, France.,Université Paris Cité, Paris, France.,Department of Pathology, Saint-Louis Hospital, AP-HP, Paris, France
| | - Matthieu Groh
- Department of Internal Medicine, Hôpital Foch, Suresnes, France
| | - Adèle de Masson
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Paris, France.,Université Paris Cité, Paris, France
| | | |
Collapse
|
47
|
Wang L, Rocas D, Dalle S, Sako N, Pelletier L, Martin N, Dupuy A, Tazi N, Balme B, Vergier B, Beylot-Barry M, Carlotti A, Bagot M, Battistella M, Chaby G, Ingen-Housz-Oro S, Gaulard P, Ortonne N. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study. Br J Dermatol 2022; 187:970-980. [PMID: 35895386 PMCID: PMC10087773 DOI: 10.1111/bjd.21791] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 07/04/2022] [Accepted: 07/22/2022] [Indexed: 12/24/2022]
Abstract
BACKGROUND Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype (pcTFH-PTCL) are poorly characterized, and often compared to, but not corresponding with, mycosis fungoides (MF), Sézary syndrome, primary cutaneous CD4+ lymphoproliferative disorder, and skin manifestations of angioimmunoblastic T-cell lymphomas (AITL). OBJECTIVES We describe the clinicopathological features of pcTFH-PTCL in this original series of 23 patients, and also characterize these cases molecularly. METHODS Clinical and histopathological data of the selected patients were reviewed. Patient biopsy samples were also analysed by targeted next-generation sequencing. RESULTS All patients (15 men, eight women; median age 66 years) presented with skin lesions, without systemic disease. Most were stage T3b, with nodular (n = 16), papular (n = 6) or plaque (atypical for MF, n = 1) lesions. Three (13%) developed systemic disease and died of lymphoma. Nine (39%) patients received more than one line of chemotherapy. Histologically, the lymphomas were CD4+ T-cell proliferations, usually dense and located in the deep dermis (n = 14, 61%), with the expression of at least two TFH markers (CD10, CXCL13, PD1, ICOS, BCL6), including three markers in 16 cases (70%). They were associated with a variable proportion of B cells. Eight patients were diagnosed with an associated B-cell lymphoproliferative disorder (LPD) on biopsy, including Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (n = 3), EBV+ LPD (n = 1) and monotypic plasma cell LPD (n = 4). Targeted sequencing showed four patients to have a mutated TET2-RHOAG17V association (as frequently seen in AITL) and another a TET2/DNMT3A/PLCG1/SETD2 mutational profile. The latter patient, one with a TET2-RHOA association, and one with no detected mutations, developed systemic disease and died. Five other patients showed isolated mutations in TET2 (n = 1), PLCG1 (n = 2), SETD2 (n = 1) or STAT5B (n = 1). CONCLUSIONS Patients with pcTFH-PTCL have pathological and genetic features that overlap with those of systemic lymphoma of TFH derivation. Clinically, most remained confined to the skin, with only three patients showing systemic spread and death. Whether pcTFH-PTCL should be integrated as a new subgroup of TFH lymphomas in future classifications is still a matter of debate. What is already known about this topic? There is a group of cutaneous lymphomas that express T-follicular helper (TFH) markers that do not appear to correspond to existing World Health Organization diagnostic entities. These include mycosis fungoides, Sézary syndrome, or primary cutaneous CD4+ small/medium-sized T-cell lymphoproliferative disorder or cutaneous extensions of systemic peripheral T-cell lymphomas (PTCL) with TFH phenotype. What does this study add? This is the first large original series of patients with a diagnosis of primary cutaneous PTCL with a TFH phenotype (pcTFH-PTCL) to be molecularly characterized. pcTFH-PTCL may be a standalone group of cutaneous lymphomas with clinicopathological and molecular characteristics that overlap with those of systemic TFH lymphomas, such as angioimmunoblastic T-cell lymphoma, and does not belong to known diagnostic groups of cutaneous lymphoma. This has an impact on the treatment and follow-up of patients; the clinical behaviour needs to be better clarified in further studies to tailor patient management.
Collapse
Affiliation(s)
- Luojun Wang
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France.,INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Delphine Rocas
- Department of Pathology, Lyon Sud, Pierre-Bénite Hospital, 69495, Lyon, France
| | - Stéphane Dalle
- Department of Dermatology, Lyon Sud, Pierre-Bénite Hospital, 69495, Lyon, France
| | - Nouhoum Sako
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Laura Pelletier
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Nadine Martin
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Aurélie Dupuy
- INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Nadia Tazi
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France
| | - Brigitte Balme
- Department of Pathology, Lyon Sud, Pierre-Bénite Hospital, 69495, Lyon, France
| | - Béatrice Vergier
- Department of Pathology, CHU de Bordeaux, Haut-Lévêque Hospital, 33600, Pessac, France.,INSERM, U1312, Université de Bordeaux, 33000, Bordeaux, France
| | - Marie Beylot-Barry
- INSERM, U1312, Université de Bordeaux, 33000, Bordeaux, France.,Department of Dermatology, CHU de Bordeaux, Saint-André Hospital, 33000, Bordeaux, France
| | - Agnès Carlotti
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Cochin Hospital, 75014, Paris, France
| | - Martine Bagot
- Department of Dermatology, Assistance Publique - Hôpitaux de Paris, Saint-Louis Hospital, 75010, Université Paris Cité, Paris, France
| | - Maxime Battistella
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Saint-Louis Hospital, 75010, Université Paris Cité, Paris, France
| | - Guillaume Chaby
- Department of Dermatology, CHU d'Amiens-Picardie, Hôpital Sud, 80054, Amiens, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France
| | - Philippe Gaulard
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France.,INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| | - Nicolas Ortonne
- Department of Pathology, Assistance Publique - Hôpitaux de Paris, Henri-Mondor Hospital, 94010, Créteil, France.,INSERM U955 Institut Mondor de Recherche Biomédicale (IMRB), Paris Est Créteil University, 94010, Créteil, France
| |
Collapse
|
48
|
Paillasse MR, Esquerré M, Bertrand FA, Poussereau-Pomié C, Pichery M, Visentin V, Gueguen-Dorbes G, Gaujarengues F, Barron P, Badet G, Briaux A, Ancey PB, Sibrac D, Erdociain E, Özcelik D, Meneyrol J, Martin V, Gomez-Brouchet A, Selves J, Rochaix P, Battistella M, Lebbé C, Delord JP, Dol-Gleizes F, Bono F, Blanc I, Alam A, Hunneyball I, Whittaker M, Fons P. Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy. Cancer Research Communications 2022; 2:1504-1519. [PMID: 36970050 PMCID: PMC10035370 DOI: 10.1158/2767-9764.crc-22-0151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Revised: 07/13/2022] [Accepted: 11/02/2022] [Indexed: 11/30/2022]
Abstract
The receptor tyrosine kinase VEGFR-3 plays a crucial role in cancer-induced angiogenesis and lymphangiogenesis, promoting tumor development and metastasis. Here, we report the novel VEGFR-3 inhibitor EVT801 that presents a more selective and less toxic profile than two major inhibitors of VEGFRs (i.e., sorafenib and pazopanib). As monotherapy, EVT801 showed a potent antitumor effect in VEGFR-3–positive tumors, and in tumors with VEGFR-3–positive microenvironments. EVT801 suppressed VEGF-C–induced human endothelial cell proliferation in vitro and tumor (lymph)angiogenesis in different tumor mouse models. In addition to reduced tumor growth, EVT801 decreased tumor hypoxia, favored sustained tumor blood vessel homogenization (i.e., leaving fewer and overall larger vessels), and reduced important immunosuppressive cytokines (CCL4, CCL5) and myeloid-derived suppressor cells (MDSC) in circulation. Furthermore, in carcinoma mouse models, the combination of EVT801 with immune checkpoint therapy (ICT) yielded superior outcomes to either single treatment. Moreover, tumor growth inhibition was inversely correlated with levels of CCL4, CCL5, and MDSCs after treatment with EVT801, either alone or combined with ICT. Taken together, EVT801 represents a promising anti(lymph)angiogenic drug for improving ICT response rates in patients with VEGFR-3 positive tumors.
Significance:
The VEGFR-3 inhibitor EVT801 demonstrates superior selectivity and toxicity profile than other VEGFR-3 tyrosine kinase inhibitors. EVT801 showed potent antitumor effects in VEGFR-3–positive tumors, and tumors with VEGFR-3–positive microenvironments through blood vessel homogenization, and reduction of tumor hypoxia and limited immunosuppression. EVT801 increases immune checkpoint inhibitors’ antitumor effects.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Gaelle Badet
- 1Evotec France, Campus Curie, Toulouse CEDEX, France
| | - Anne Briaux
- 1Evotec France, Campus Curie, Toulouse CEDEX, France
| | | | - David Sibrac
- 1Evotec France, Campus Curie, Toulouse CEDEX, France
| | | | | | | | | | - Anne Gomez-Brouchet
- 4Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse, Occitanie, France
| | - Janik Selves
- 4Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse, Occitanie, France
| | - Philippe Rochaix
- 4Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse, Occitanie, France
| | - Maxime Battistella
- 5Université de Paris, Department of Pathology, AP-HP Hôpital Saint Louis, INSERM U976, Paris, France
| | - Céleste Lebbé
- 6Université de Paris, Department of Dermatology, AP-HP Hôpital Saint Louis, INSERM U976, Paris, France
| | - Jean-Pierre Delord
- 4Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse, Occitanie, France
| | | | | | | | | | | | | | - Pierre Fons
- 1Evotec France, Campus Curie, Toulouse CEDEX, France
| |
Collapse
|
49
|
Bontoux C, de Masson A, Thonnart N, Ram‐Wolff C, Caraguel F, Batista L, Carpentier S, Moins‐Teisserenc H, Rivet J, Vignon‐Pennamen M, Marie‐Cardine A, Bagot M, Battistella M. Large-cell transformation is an independent poor prognostic factor in Sézary syndrome: analysis of 117 cases. Br J Dermatol 2022; 187:815-817. [PMID: 35791764 PMCID: PMC9805072 DOI: 10.1111/bjd.21738] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 06/27/2022] [Accepted: 07/02/2022] [Indexed: 01/09/2023]
Affiliation(s)
- Christophe Bontoux
- Department of PathologyHôpital Saint‐Louis, AP‐HPParisFrance,INSERM U976, HIPIParisFrance,Université de ParisInstitut de Recherche Saint‐LouisParisFrance
| | - Adèle de Masson
- Department of DermatologyHôpital Saint‐Louis, AP‐HPParisFrance,INSERM U976, HIPIParisFrance,Université de ParisInstitut de Recherche Saint‐LouisParisFrance
| | - Nicolas Thonnart
- INSERM U976, HIPIParisFrance,Université de ParisInstitut de Recherche Saint‐LouisParisFrance
| | - Caroline Ram‐Wolff
- Department of DermatologyHôpital Saint‐Louis, AP‐HPParisFrance,INSERM U976, HIPIParisFrance,Université de ParisInstitut de Recherche Saint‐LouisParisFrance
| | | | | | | | - Hélène Moins‐Teisserenc
- Université de ParisInstitut de Recherche Saint‐LouisParisFrance,Clinical Haematology LaboratoryHôpital Saint‐Louis, AP‐HPParisFrance,INSERM U1160ParisFrance
| | | | | | - Anne Marie‐Cardine
- INSERM U976, HIPIParisFrance,Université de ParisInstitut de Recherche Saint‐LouisParisFrance
| | - Martine Bagot
- Department of DermatologyHôpital Saint‐Louis, AP‐HPParisFrance,INSERM U976, HIPIParisFrance,Université de ParisInstitut de Recherche Saint‐LouisParisFrance
| | - Maxime Battistella
- Department of PathologyHôpital Saint‐Louis, AP‐HPParisFrance,INSERM U976, HIPIParisFrance,Université de ParisInstitut de Recherche Saint‐LouisParisFrance
| |
Collapse
|
50
|
Hamdan D, Pamoukdjian F, Lehmann-Che J, de Bazelaire C, Vercellino L, Calvani J, Battistella M, Bertheau P, Falgarone G, Bousquet G. A massive open online course to teach undergraduate medical students in oncology: keys of success. Heliyon 2022; 8:e11306. [DOI: 10.1016/j.heliyon.2022.e11306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Revised: 08/30/2022] [Accepted: 10/24/2022] [Indexed: 11/08/2022] Open
|